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ABSTRACT 
Ghosh, Soumitra. PhD., Purdue University, December 2015. Stress Granules modulate 




Microglial cells in the brains of Alzheimer’s patients are recruited to amyloid beta (Aβ) 
plaques and exhibit an activated phenotype, but are defective for plaque removal by 
phagocytosis. To explore the molecular basis for these phenomena, I hypothesized that 
defects in the functions of the protein-tyrosine kinase SYK, which is important both for 
macrophage activation and phagocytosis, might underlie much of this pathology. Recent 
evidence from our lab indicates that SYK can associate with stress granules, 
ribonucleoprotein particles that form in stressed cells and contain inactive translation 
initiation complexes. I found that microglial cell lines and primary mouse brain microglia, 
when stressed by exposure to sodium arsenite or Aβ(1-42) peptides or fibrils, form 
extensive stress granules to which the tyrosine kinase, SYK, is recruited. SYK enhances 
the formation of stress granules as evidenced by the inhibition of stress granule formation 
by small molecule inhibitors, knockdown of SYK expression by shRNA and SYK 
haploinsufficiency in mouse microglial cells. SYK is active within the resulting stress 
granules where it catalyzes the phosphorylation of stress granule-associated proteins on 
tyrosine.  SYK-dependent stress granule 
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formation stimulates the production of reactive oxygen and nitrogen species. These are 
toxic to neuronal cells as demonstrated by a co-culture assay using stressed microglial 
cells and HT22 neuronal cells. The ability of microglial cells to phagocytose E. coli is 
blocked by SYK inhibitors. The sequestration of SYK into stress granules inhibits the 
ability of microglial cells to phagocytose either E. coli or Aβ fibrils. Microglial cells from 
aged mice are more susceptible to the formation of stress granules than are cells from 
young animals. Stress granules containing SYK and phosphotyrosine are prevalent in the 
brains of patients with severe Alzheimer’s disease, suggesting that the sequestration of 
SYK into stress granules is part of the pathology of the disease. Phagocytic activity can 
be restored to stressed microglial cells by treatment with IgG independent of the epitope 















Microglial cells (MG) are the professional macrophages of the central nervous system. 
Among their many tasks is the removal from the brain of aggregates of β-amyloid (Aβ), 
which is formed from a proteolytic product of amyloid precursor protein (1). The 
persistent accumulation of β-amyloid plaques is a characteristic of Alzheimer’s disease 
(AD), a serious neurodegenerative disorder affecting millions of patients worldwide. MG 
are attracted to sites of Aβ deposition, which they recognize through a variety of cell 
surface receptors, and are capable of Aβ removal through phagocytosis (2, 3). Impaired 
microglial activity, as exhibited by defective removal of Aβ plaques, is particularly 
associated with the later stages of AD as plaques accumulate (4-6). These plaques still 
attract MG, but are refractory to phagocytosis. While MG can phagocytose Aβ fibrils, 
they also become activated as a consequence of receptor engagement by Aβ (7-9). The 
activation of MG is problematic as the resulting inflammatory response can damage 
neighboring neuronal cells (9). Compelling evidence for an important role of MG in AD 
comes, in part; from large scale studies of genes associated with AD that directly 
implicate inflammatory responses of MG as critical for AD pathology. Products of genes 
with identified associations with AD include Triggering Receptor Expressed on Myeloid 
2 
 
Cells 2 (TREM2), TYRO Protein Tyrosine Kinase Binding Protein (TYROBP) and CD33 
(10-15). The myeloid receptor TREM2 functionally associates with TYROBP and 
promotes the internalization of bacteria and apoptotic neurons and recruits MG to Aβ 
plaques (16-19). Loss-of-function mutants promote inflammatory responses, decrease 
phagocytosis and predispose patients to AD (10). CD33 is dysregulated in MG in AD 
brain and is associated with reduced uptake of Aβ and increased numbers of activated, 
pro-inflammatory MG (20).  
 Many phagocytic receptors contain or are associated with proteins such as 
TYROBP that contain immunoreceptor tyrosine-based activation motifs (ITAMs) (21, 
22). Receptor engagement initiates the phosphorylation of the two ITAM tyrosines 
leading to a physical interaction with the tyrosine kinase, SYK (23). Signaling through 
ITAM receptors is attenuated by receptors with immunoreceptor tyrosine-based 
inhibitory motifs (ITIMs) such as CD33 (24). Since SYK is essential for both 
phagocytosis in macrophages and for the receptor-mediated activation of inflammatory 
responses (25, 26), two events that are disrupted in MG from AD brains, it would appear 
to be a prime candidate for a critical mediator of AD pathology. An important question is 
how the function of SYK might be disrupted in aged or stressed MG.  
 MG in aged and AD brain fail to clear Aβ plaques, but display an activated, pro-
inflammatory phenotype (4-6). How aging and other stresses affect MG to alter their 
homeostatic functions is unclear. Eukaryotic cells respond to external stresses via the 
formation of ribonucleoprotein (RNP) complexes scaffolded by RNA-binding proteins 
that self-associate. Examples of RNP aggregates include stress granules (SGs), which 
contain stalled initiation complexes and their associated mRNAs (27, 28). An association 
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of RNP aggregates with neurodegenerative diseases is well documented and mutations in 
RNA-binding proteins that promote self-assembly can be drivers of motor neuron 
diseases (29, 30). Similarly, defective clearance of SGs leads to the pathological 
accumulation of RNP particles and underlies the pathology of amyotrophic lateral 
sclerosis, Huntington’s disease (HD), frontotemporal lobar degeneration (FLD) and AD 
(31-40). 
 Large scale proteomic screens from our laboratory have identified multiple SG-
associated proteins as binding partners and substrates for SYK (41-43). SYK is recruited 
to SGs in some cells when exposed to sodium arsenite (SA) or proteasome inhibitors. In 
this study, I find that SYK also is recruited to SGs that form in MG, not only in response 
to sodium arsenite, but also in response to Aβ peptides or fibrils. Chronic stress leads to 
the formation of persistent SGs in MG in which active SYK is sequestered, leading to the 
constitutive production of reactive metabolites and the inhibition of phagocytic activity. 
Cytoplasmic aggregates containing SYK and phosphotyrosine are more pronounced in 
MG in the brains of patients with advanced AD. Based on this information, I propose a 
model in which the production of SGs and the corresponding misregulation of SYK 
directly contributes to AD pathology. Interestingly, the impaired phagocytic activity of 
stressed MG can be restored by the induced relocation of SYK from the SG to the plasma 
membrane by treating cells with Immunoglobulin G, suggesting a mechanism by which 






1.2 Alzheimer’s disease and its causes 
 
Alzheimer’s disease (AD) is one of the most prevalent neurodegerative disorders in the 
world. According to recent statistics, five million Americans are living with AD in 2015, 
a number predicted to rise to sixteen million by 2050 (44).  A substantial increase in the 
older population is also considered a major contributor to this alarming increase in AD 
patients. AD is categorized into two categories: early-onset AD (EAD) and late-stage AD 
(LAD). Mild-cognitive impairment (MCI) is a cognitive dysfunctional condition that 
precedes AD and contributes to its progression (45-48). Currently we do not have a 
method to detect AD in its early stages (49). The clinical symptom of AD develops much 
later than the initial onset of the disease; hence early detection is extremely difficult. The 
primary cause of dementia in AD is still unknown (50). The term AD was first coined in 
1910 by Dr. Kraepelin following its discovery in 1906 by Dr. Alois Alzheimer. 
Considerable progress in understanding the complexity of the disease has not yet led to a 
successful therapeutic intervention. Hence we do not have a successful drug candidate to 
cure AD.  
1.3 Amyloid beta and Tau pathology 
 
The patients suffering from AD encounter reduced memory, cognition dysfunction and 
massive neuronal cell death over time. Post mortem examination of AD patients’ brains 
have revealed amyloid beta (Aβ) plaques and tau fibrillary tangles as the two hallmarks 
of AD (10, 45, 46, 51-53). Aβ aggregates into oligomers, fibers and plaques in the 
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diseased brain that hinder the normal functioning of brain in various ways (54-59). Aβ is 
amino acid peptide sequence of variable size (38, 40 and 42 amino acids) that is formed 
as result of cleavage of amyloid precursor protein (APP) by two enzymes: β-secretase 
and ɣ-secretase. It is considered that Aβ deposition is an initiating pathological event in 
AD. Over time Aβ undergoes different stages of aggregation, forming soluble oligomers, 
insoluble oligomers and insoluble fibrils (60-63). These Aβ deposits impair synaptic 
functioning resulting in chronic neurodegeneration ultimately leading to excessive 
neuronal cell death, cognitive impairment and severe dementia (64-67). Targeting Aβ 
deposition through drugs, antibodies and small molecule inhibitors have proven to be 
effective in alleviating the symptoms to a certain extent, but not completely (68-73). 
 Tau is another key protein involved in neurodegeneration. Tau is a microtubule-
associated protein found in mature neurons where it stabilizes microtubules. In normal 
brain, tau is both O-GlcNAcylated and phosphoryled at low levels. In AD brain, 
hyperphosphorylation of tau leads to impairment of its normal biological activity.  In 
neurodegenerative conditions, tau becomes N-glycosylated; and this glycosylation makes 
it more prone to phosphorylation by protein kinase A (PKA), glycogen synthase kinase 3 
beta (GSK-3β) and cyclin dependent kinase 5 (Cdk5). Additionally protein phosphatase 
A (PP-2A) activity is decreased, but calmodulin-dependent protein kinase II (CaMKII), 
PKA and mitogen activated protein kinase (MAPK) activities are increased in the CNS 
(69, 74-84) .  The hyperphosphorylation of tau leads to a breakdown of the microtubule 
network and subsequent formation of paired helical filaments which make up 
neurofibrillary tangles. Finally axonal transport is compromised resulting in retrograde 











Figure1.1  Schematic diagram of Alzheimer’s disease hallmarks 
In human AD brain, Amyloid beta protein aggregates to form 
amyloid plaques as shown in the figure. TAU protein also hyper-
phosphorylates to form neurofibrillary tangles as shown above. 




1.4 Oxidative stress in AD 
 
Apart from Aβ and tau pathology, there are several other factors that contribute to AD 
pathology. Maintenance of cellular redox levels is crucial for the normal functioning of 
neurons. Studies on AD brains suggest excessive oxidative stress damages neurons and 
other supporting cells in the brain. Common oxidants such as hydrogen peroxide (H2O2), 
superoxide (O2−) and peroxynitrite (ONOO−) are highly elevated in AD brains (74, 86-
89). Additionally there is a decrease in antioxidants such as glutathione (GSH) and its 
supporting enzymes, glutathione peroxidase (GPX), and glutathione S-transferase (GST) 
(90). The increase in oxidative stress is mainly attributed to elevated oxidative 
phosphorylation in damaged mitochondria. AD progression impairs the normal efficiency 
of the mitochondria and leads to a feed-forward mechanism of superoxide production 
(91-93). Increase in ROS/ RNS promotes neuroinflammation through increase in 
cytokines, activation of apoptotic pathways and overexpression of transcription factors 
leading to neuronal cell death (85, 92, 94-100). 
 
1.5 Genes, proteins and kinases involved in AD 
 
AD is also classified into two categories, sporadic and familial, based on its causative 
origin. Our knowledge about the genes involved in AD mainly comes from studies 
involving familial AD cases. Studies for decades have revealed that several genes and 




 Amyloid precursor protein (APP) is a type1 transmembrane protein that is highly 
expressed in neurons and astrocytes. Proteolytic processing of APP leads to 
amyloidogenic pathways (101, 102). APP is cleaved to generate Aβ peptides, soluble 
APPβ and beta C-terminal fragments β-CTF (103, 104). APP on the cell surface is 
generally internalized allowing Aβ to be generated within the endocytic pathway and then 
released into the extracellular space (105). Recessive genetic mutations in APP such as 
A673V and E693Δ are reported to cause early-onset AD (106). Mutations such as the 
Swedish mutation (KM670/671NL) increases plasma Aβ levels by altering β-secretase 
enzyme efficiency whereas the Dutch mutation (E693Q) occurs in the Aβ domain and 
results in excess Aβ aggregation (107, 108).  
Presenilin 1 (PSEN1) and presinilin 2 (PSEN2) are integral membrane proteins that are 
important components of the ɣ-secretase complex, which is responsible for cleaving APP 
into Aβ fragments (109, 110). Their presence in the endoplasmic reticulum makes them 
an important component of protein processing. To date, 185 dominant mutations have 
been identified in PSEN1 that account for 80% of early-onset familial AD and 13 
dominant pathogenic mutations have been identified in PSEN2 (111, 112).  
 A Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) is 
a metalloproteinase domain-containing protein that is considered a major α-secretase and 
is responsible for cleaving the APP ectodomain. ADAM10 mutants Q170H and R181G 
increase Aβ levels in vitro and in AD transgenic mice (113-116).  
 Apolipoprotein E (APOE) is a prime risk gene in AD. It is a pleiotropic 
glycoprotein that is highly expressed in liver, brain and macrophages. It regulates the 
mobilization and redistribution of cholesterol. APOE in the brain is required for neuronal 
9 
 
growth, nerve repair and regeneration, immune response and activation of lipolytic 
enzymes. APOE exists in three different isoforms: APOEε2, APOEε3 and APOEε4. 
APOEε4 has been reported to increase the risk of familial and sporadic early- and late-
onset AD. The increase in APOE expression can increase plaque formation and 
accumulation (51, 106, 117-119).  
 Evidence suggests that cellular prion protein PRNP plays an important role in 
several neurodegenerative diseases including AD. It has a very high binding affinity for 
Aβ oligomers as confirmed in human AD brains. It binds to the tyrosine kinase FYN, 
which phosphorylates N-methyl D-aspartate receptor subtype 2B (NR2B) subunit and 
TAU on tyrosine. Interestingly, FYN phosphorylates TAU postsynaptically to induce Aβ 
toxicity mediated through the N-methyl-D-aspartate (NMDA) receptor (120-127).  
 Ephrin receptor B2 (EPHB2) is a tyrosine kinase that has a high affinity for Aβ 
oligomers and helps in regulating the synaptic localization and function of NMDA 
receptors. Studies have revealed that Aβ oligomers can bind EPHB2 and lead to its 
proteosomal degradation.  This affects NMDA receptor signaling, resulting in defective 
long term potentiation (LTP) (66, 120, 128-130).  
 Evidence has suggested an impairment of calcium signaling in AD brains. Aβ 
induced calcium elevation activates the calcium-dependent phosphatase calcineurin, 
which in turn leads to the nuclear localization and increased transcriptional activity of 
nuclear factor of activated T cells (NFAT). GSK3 phosphorylates NFAT to keep it out of 
the nucleus which in turn increases Fas ligand (FASL) levels. Calcium /calmodulin 
dependent kinase kinase 2 (CAMKK2) is a serine /threonine kinase whose activity is 
directly dependent on calcium influx in the brain (131-138). The CAMKK2- 5' adenosine 
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monophosphate-activated protein kinase (AMPK) pathway mediates early synaptotoxic 
effects of Aβ oligomers through Tau phosphorylation (139, 140).  
 Mitochondrial damage is an early event observed in AD cell–culture and animal 
models. Centaurin-α1 is an Arf GTPase-activating protein that promotes ADP 
ribosylation and is required for normal dendritic development. It interacts with RAS and 
Ras-E26-like kinase 1 (Elk-1) in AD brains. Mitochondrial permeability is directly 
regulated by centaurin-α1 and Elk-1. Ras-Elk-1 pathway mediated mitochondrial damage 
leads to loss of dendritic spines and spine structural plasticity (115, 141-148).  
5' adenosine monophosphate-activated protein kinase (AMPK) and mammalian target of 
rapamycin (mTOR) pathways are directly modulated by Ras and MAPK in neurons 
leading to neuronal cell death. mTOR is a serine/threonine kinase that plays a critical role 
in several cellular processes such as maintaining cell size, cell proliferation and 
autophagy through regulation of protein synthesis. Specifically in neurons, mTOR plays a 
role in synaptic plasticity, axon pathfinding and regeneration, dendrite arborization and 
spine morphology maintenance. In AD brains, mTOR signaling is unregulated in both 
mouse models and human samples. This manifests in an early cognitive decline and 
reduced autophagy that can be rescued by inhibition of mTOR by rapamycin. 
Additionally, AMPK and MAPK4 further phosphorylate TAU on S262 in the 
microtubule-binding domain. This in turn promotes tau aggregation and hinders its 
clearance (149, 150). 
 Two other kinases that play an important role are Cdk5 and c-Jun N-terminal 
kinase 3 (JNK3). ER stress is a common phenomenon observed in AD. ER stress 
activates JNK3 that further phosphorylates APP. Thus increased JNK3 activity in AD 
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brain facilitates endocytosis of APP and further processing of Aβ (142, 151-160). Cyclin 
dependent Kinase (Cdk5) is a proline-directed serine/ threonine kinase that also plays a 
critical role in AD progression. In neurons, Cdk5 binds to its activator p35 or p39 to 
maintain its activation. Later in AD, Cdk5 is over activated by the p25 component of p35 
and this leads to synaptic failure, which promotes neuronal cell death and loss of learning 
and memory. This overactivation leads to Tau aggregation, Aβ accumulation, activation 
of downstream transcription factors, and increased oxidative stress in the brain (90, 152, 
161-166).   
 GSK3β is modulated by Wnt signaling and insulin levels in the brain. GSK3 also 
reduces acetylcholine synthesis and promotes neuronal apoptosis.  GSK3β plays a pivotal 
role in AD signaling cascade leading to hyperphosphorylation of tau and increased Aβ 




Figure 1.2 Schematic chart of Alzheimer’s disease causative 
factors 
In AD, both environmental and genetic factors contribute 
towards the manifestation of the disease. Environmental 
factors as mentioned above are considered the cause behind 
80% AD cases. These factors could also lead to mutations in 
genes described in genetic factors. Genetic factors like 
Amyloid precursor protein interact with other genes and 
proteins that predispose individual to AD.  
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1.6  Neuroinflammation in AD 
 
Neuroinflammation is a crucial event that contributes to AD pathogenesis and alters the 
neuronal compartment of the brain. Misfolded and aggregated protein complexes bind to 
pattern recognition receptors on microglia and astroglia triggering an innate immune 
response (131, 141, 169-174). This response results in the release of inflammatory factors 
that increase disease severity. High throughput screening studies have revealed that many 
genes that increase the risk for sporadic AD are actually encoded in glial cells. Other 
external factors like obesity, metabolic disorders, exposure to toxins, stress and high 
cholesterol all indicate interference with the immunological processes of the brain. Our 
ability to understand and control such immune reactions in the brain would be an 
important step to prevent or delay neurodegenerative diseases (69, 74, 87, 94, 141, 169-
171, 175-178).  
 The innate immune response toward amyloid deposition and neurofibrillary tangle 
formation is considered a prime pathological event in AD. It has been observed that in 
AD brains amyloid plaques are always surrounded by activated microglial cells and 
astrocytes. The complement-mediated immune system has also been found to be 
activated in amyloid- and tau tangles-positive AD brains (78, 141, 179-181). Once the 
amyloid plaques or tangles are formed, the immune system mediates a local 
inflammatory response that directs the immune cells to the site of deposition and 
promotes secondary inflammation. Immune-based therapies have been designed to 
remove amyloid peptide aggregates from the brain of AD animal models. Several generic 
non-steroidal anti-inflammatory drugs have been shown to be slightly effective against 
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AD progression (100, 182-184). The nonsteroidal anti-inflammatory drug (NSAID) R-
flurbiprofen was used in a recent Phase II clinical trial in patients affected with mild AD 
and showed a 62% decline in AD symptoms. These NSAID’s mainly target 
cyclooxygenase 2 (COX2), which is found to be up regulated in AD brains and enhances 
neuroinflammation (182, 185-188). NSAIDs such as ibuprofen and indomethacin target 
cyclooxygenases nonselectively and suppress prostaglandin production by microglial 
cells during inflammatory reactions (189, 190). Few agents directly target β-secretase and 
APP-CTF-β thereby hindering proteolysis of APP and APP-CTF-β respectively.  In the 
brain, the resident immune cells sense the alterations in the tissue through receptors for 
damage associated molecular patterns (DAMPs) (191). In this case, DAMPs are amyloid 
plaques, tau fibrillary tangles and misfolded proteins. The extreme inflammatory 
condition observed in AD is driven mainly by CNS-resident immune cells —microglia, 
perivascular myeloid cells and astrocytes. 
 
1.7 Astrocytes- Activation and Inflammation 
 
Astrocytes and microglia are the two major glial cell populations of the brain. They both 
communicate with neurons to maintain homeostasis and proper functioning of the brain. 
In addition to participating in the immune response, astrocytes recycle glutamate, and 
regulate CNS blood flow, blood brain barrier formation and maintenance, synaptogenesis, 
myelination, metabolism, and release of transmitters (64, 74, 97, 141, 192-195). They are 
the predominant cells in the mammalian brain. Their role has been documented in several 
neuro-developmental diseases such as Rett Syndrome and Fragile X Syndrome and in 
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neurodegenrative disorders such as multiple sclerosis (MS), Alzheimer’s disease, 
amyotrophic lateral sclerosis (ALS) and HD (192, 196-199). Developmental studies have 
suggested that astrocytes develop by gliogenesis, which occurs after neurogenesis. 
Although it is not well understood how astrocytes develop from neural stem cells, it is 
believed that they follow a similar pattern as neurons. Astrocyte precursors are formed 
and migrate from stem cells. A maturing postnatal astrocyte is formed, from which an 
adult astrocyte develops. Local conditions and patterns help them develop heterogeneity 
(174, 192, 200-205).  
 Normal aging is known to be accompanied by mild inflammation, reactive gliosis 
and oxidative stress. In AD, astrocytes show some effects similar to microglia, but also 
have beneficial properties.  They help in removing Aβ without the release of excessive 
opsonins or cytokines. After activation, astrocytes also release helpful growth factors 
such as nerve growth factor (NGF), S100β (neurotrophic signaling molecule), brain 
derived neurotrophic factor (BDNF) and neurotrophin 3 (NT-3) (206-208). Hence they 
help other immune cells as well as neurons to control the release of toxic substances 
under inflammatory conditions. Astrogliosis is an event observed in AD brain, 
represented by proliferation of astrocytes in response to neuronal cell death and Aβ 
stimulation. Chronic inflammation in AD leads to an increase in chemokines like IL-6, 







 1.8 Microglia – Macrophages of the brain  
 
Microglia are the tissue-resident macrophages of the brain. They are the first line of 
defense for the brain against any insult or threat. The four most important functions of 
microglia are immune surveillance, apoptotic clearance, neurogenesis and synaptic 
pruning. MG share a common myeloid origin with macrophages, but have a different and 
distinct morphology and function (194, 211, 212). These cells develop in the bone 
marrow and then migrate to the brain and then adapt to their residing locations. Studies in 
mice have revealed that microglia originate in the yolk sac in a pU1-dependent and Myb-
independent manner from erythromyeloid progenitors (EMPs). During development of 
the zebra fish brain, the precursor cells spread within the embryo and then, 48 hrs post 
fertilization, invade the brain and establish a microglial population (211-216). In 
neurodegenerative diseases like AD, patients suffer from microglial over activation and 
blood brain barrier defects arising from chronic inflammation. It is believed that 
microglia poorly phagocytose amyloid plaques and promote AD pathology by releasing 
proinflammatory cytokines. MG develop a ramified and activated phenotype around Aβ 
amyloid plaques in AD and lose their intrinsic beneficial role during the disease 
progression. Instead they acquire a toxic phenotype which is evident from the increasing 


















Figure 1.3 Schematic chart diagram of microglial cell in AD 
Microglia are the prime immune cells in the brain. They 
constantly survey their surroundings for the presence of 
pathogens and cellular debris. It is also responsible for 
maintaining the homeostasis of the brain. When microglial 
cells encounters misfolded or aggregated proteins like Abeta 
or tau in AD, it triggers an innate immune response 
characterised by release of inflammatory chemokines and 
ROS, which ultimately leads to neuronal cells death. 
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1.9 Various functions of Microglia 
 
There are several important functions of microglia in the context of brain development, 
homeostasis and neuronal connectivity. These different functions are described below. 
 
1.9.1 Phagocytosis of debris and foreign bodies. 
Phagocytosis is the most important and basic function of microglial cells. These are the 
cells that attack any kind of foreign bodies or debris found in healthy brain. The MG 
release multiple soluble cytotoxins, neurotrophins and immunomodulatory factors that 
help in clearing debris by phagocytosis. Chemokines released by degenerated neurons 
also act as a chemo-attractant for MG to detect their site of action.  Studies have revealed 
that MG are highly motile at any stage and have filopodia-like protrusion used for 
continuous surveillance of the microenvironment (222-224). In a healthy brain, to 
facilitate successful repair of the microenvironment, MG create an environment 
necessary for regeneration. In order to do so, they release numerous cytokines, ROS/RNS, 
chemokines and other soluble mediators at the spot of repair. These chemicals attract 
phagocytotic and repair helper cells, which in turn contribute to tissue repair. This kind of 
repair activity has been observed in remyelination of damaged axons (131, 172, 174, 225, 
226).   
  For the purpose of phagocytosis, MG express two major classes of receptors, toll 
like receptors (TLRs) and receptors that recognize phosphatidylserine (PS). TLRs are 
mainly responsible for phagocytosis of pathogens and any unnatural bodies in the brain 
(227-230). This process leads also to pro-inflammatory responses and the release of 
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tumor necrosis factor α (TNF-α), interleukin-1 (IL-1), NO and ROS. Other groups of 
phagocytotic receptors in MG include scavenger receptors, RAGE, Scara receptors, Fcɣ 
receptors and integrins (54, 148, 151, 225, 231-237). These receptors are discussed in 
details later on. 
1.9.2 Engulfment of apoptotic cells.  
Apoptosis or programmed cell death is an essential step in brain development.  Microglia 
play a significant role in removing apoptotic neurons during CNS development and in the 
adult brain. Studies suggest that in brain, apoptotic cells express “eat-me” signals that 
allow MG to recognize these cells and eventually remove them. Phosphatidylserine (238-
240) (PS) is such a signal and binds PS receptors including milk fat globule epidermal 
growth factor 8 (MFG-E8) present on the microglial surface. The level of expression of 
PS determines the phagocytic behavior of MG. In zebrafish, it has been observed that 
brain-specific angiogenesis inhibitor 1 (BAI1) and T-cell immunoglobulin mucin 
receptor 4 (TIM4) proteins are required by microglial cells to perform phagocytosis of 
apoptotic cells. BIA1 promotes phagosomal cup formation whereas TIM4 helps in 
maintaining the structure of the phagosomes (241). Other signals like  adenosine tri-
phosphate (ATP) or lysophosphatidylcholine attract the microglia toward apoptotic 
neurons (241). In addition, apoptotic neurons release the chemokine fractalkine 
(CX3CL1) into the environment to send a “find-me” signal for the microglia (241). 
Another interesting signal that helps microglia in finding apoptotic cells are generated 
due to changes in Ca
2+
. At the site of injury, these spike Ca
2+
 signals lead to the release of 
ATP (80, 242).  The resulting ATP gradient activates the P2y12 purinergic receptor (243, 
244) on microglial cells, attracting them to the site of the injured neuron.  MG also are 
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known to trigger neuronal cell death during cerebellum and hippocampus development. 
This process is known as “phagoptosis” and it involves the killing of Punkinje neurons by 
production of reactive oxygen species and superoxide anions. These ROS are produced 
when CD11b integrin and DAP12 are activated in MG. Studies have also revealed that 
release of TNF-α in activated microglia hastens the process of phagoptosis (245, 246). 
1.9.3 Participation in neurogenesis and brain wiring.  
MG had been considered non-functional during neurogenesis for decades. Recently, 
studies have revealed that they actually play an important role in neurogenesis. MG 
produce or support the production of neurotrophic factors such as insulin growth factor 1 
(IGF-1) to promote nerve growth and survival during neurogenesis (247). Interestingly, 
different signaling molecules are released by microglia during development based on 
their location. For example in layer V, the IGF-1 signaling pathway is activated by MG 
whereas in the subventricular zone, interleukin 1 beta (IL-1β) and interferon gamma 
(IFNɣ) pathways are activated (169, 248-255). MG promote wiring of the brain, 
specifically at the regions close to dopaminergic and neocortical interneurons. Apart from 
a direct role in neurogenesis, some location specific MG also impact proliferation of 
neuronal precursor cells (NPC). The activation of MG inversely correlates with the 
number of NPC and directly impacts glial proliferation. Hence the fewer activated MG 
there are, the more NPC are found in the CNS (256-260).   
1.9.4 Maintenance of synaptic pruning. 
Synaptic pruning is one of most interesting functions of MG. Synaptic pruning is a 
process where synapses are remodeled during early and late postnatal stages of neuronal 
connections. In postnatal mouse brains, microglial synaptic pruning is observed in 
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hippocampus, cerebral cortex and thalamus (261, 262). The complement system, which is 
considered an integral part of the infection fighting process, plays an important role in 
brain wiring and synaptic pruning. C1q and C3 complement receptors in particular are 
involved in synaptic pruning through the removal of synapses through phagocytosis. It is 
suggested that neuronal activity is continuously sensed by microglia in the brain (263-
266).    
 
1.10 Microglial cells in Alzheimer’s disease 
 
AD is strongly associated with a state of chronic inflammation in the brain, a process in 
which MG play a significant role. The role of MG in AD became clearer when TREM2 
(gene encoding the TREM2 receptor) and the gene coding for its associated protein, 
TYROBP/DAP12, were found to be directly associated with late onset Alzheimer’s 
disease through GWAS studies. TREM2 is a major phagocytotic receptor in MG. 
TREM2 is essentially required for phagocytosis of debris and Aβ plaques in AD. It also 
controls the inflammatory response of MG and helps in promoting survival and repair 
pathways in AD (18, 19, 226, 231, 267, 268). In addition, mutations in the microglial 
gene colony stimulating factor 1 receptor (CSF1R) play an important role in 
neurodegeneration.  CSF1R is required for normal growth of resident microglia in 
developing brain. In EAD, CSF1R helps in microglial activation that promotes 
phagocytosis of Aβ plaques and TAU fibrils. Interestingly, in LAD CSF1R upregulation 
promotes over-activation of MG leading to an increase in inflammation (269, 270). 
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In AD, aggregation of beta amyloid plaques and tau fibrillary tangles within cells as well 
as in extracellular regions leads to over activation of microglia and neuronal cell death. 
Evidence suggests that Aβ fibrils attract MG.  MG elevate expression of MHC class II, a 
sign of activation. In vivo studies in AD transgenic mice have shown  that when MG 
come in contact with Aβ plaques and tau tangles they release numerous immune 
molecules including granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-1, 
IL-12, IL-23 and complement proteins. In vitro studies have implicated additional 
cytokines and chemokines including tumor necrosis factor (TNF-α, IL-1b, IL-6, 
macrophage inflammatory protein (MIP)1a, macrophage chemotactic protein (MCP)-1, 
IL-8, macrophage-colony stimulating factor (M-CSF) and IL-12 as factors released by 
activated MG. Activation of the complement cascade (C1qB, C3 and C4) is also observed. 
Microglial specific receptors CD14, CD36, CD47, α6β1, class A scavenger receptor, 
TLRs and receptor for advanced glycation endproducts (RAGE) are involved in the 
initiation of these inflammatory pathways. All of these factors in a combined manner 
contribute to neuroinflammation in AD (56, 91, 148, 172, 209, 225, 248, 271-276). 
Complexities arise when we try to define the role of such neuroinflammation in AD brain. 
Evidence suggests that this inflammatory response is beneficial to the brain in the early 
stages of disease progression, but prolonged chronic inflammation forces MG to attain an 
altered state that causes more harm than good. MG at this stage continue secreting 
neurotoxic chemokines, cytokines, ROS, RNS and superoxide ions which worsens the 




Like other cells of myeloid origin, MG perform phagocytosis with high efficiency in 
healthy brain. In AD brain, MG are supposed to phagocytose Aβ and degrade Aβ by 
microglial proteases, which are key mechanisms for removal of these aggregates from the 
brain. Studies have indicated that in moderate or later severe stages of AD, the 
phagocytosis of Aβ plaques and fibrils by MG is impaired. The increasing burden of Aβ 
plaques in the AD brain increase chronic inflammation and leads to cellular senescence 
(219, 282, 283). Senescence in MG results in a state where MG cannot phagocytose but 
generates pro inflammatory factors, cytokines and reactive species. Soluble Aβ (sAβ) has 
been reported to be engulfed by MG through both phagocytosis and pinocytosis. 
Pinocytosis is an endocytic process where MG uptake soluble Aβ by forming an 
invagination. The Aβ is then suspended in small hollow vesicles. The content of these 
vesicles are further hydrolyzed in lysosomes and degraded (284, 285).   
 Genetic mutations in microglia have been found to promote AD pathogenesis. For 
example, the TREM2 adaptor molecule, TYROB/DAP12 is associated in LOAD 
pathogenesis. TREM2 is one of the major receptors required by MG for phagocytosis of 
debris and foreign bodies. DNAX-Activation Protein 12 (DAP12) is an adaptor receptor 
protein that helps in ITAM receptor signaling in MG. It also interacts with CSF1R in 
Hereditary Diffuse Leukoencephalopathy with Spheroids (HDLS) pathology (16, 21, 231, 
286, 287). Genome wide association studies (GWAS) studies revealed an increase in 
microglia of CD33 (Siglec-3) in human AD brain, which is correlated with increased 
insoluble Aβ levels. CD33 receptors bear an ITIM that is required for receptor signaling 
in MG. Increase in CD33 activity in AD mouse models revealed reduced uptake Aβ 
clearance by MG. This suggests that CD33 activity inhibits phagocytosis ability of MG 
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through ITIM receptor signaling (14, 288-290). TREM2 on the other hand is involved in 
cytokine and chemokine production, phagocytosis and MG cell motility. These studies on 
microglial specific genes have provided us with deeper insight in understanding the role 
of MG in AD progression and specifically, sporadic AD.   
 
1.11 SYK kinase and its activation  
 
SYK is a non-receptor protein-tyrosine kinase located in the cytoplasm. SYK was 
initially discovered as a 40 kDa catalytic fragment by two independent groups as 
published in Zioncheck et al. and Kobayashi et. al. Later, the full-length72 KDa enzyme 
was identified through the use of specific antibodies (291, 292). SYK is mainly expressed 
in spleen and thymus and is found in many hematopoietic cells including B cells, 
thymocytes, erythrocytes, macrophages and platelets (271, 293, 294).  SYK also has been 
found in a subset of non-hematopoietic cells including epithelial, endothelial, fibroblast, 
neuronal cells and some non-neuronal brain cells (295, 296). SYK is well known to play 
crucial roles in adaptive immune receptor signaling, innate immune signaling, platelet 
activation, cellular adhesion, cellular motility, vascular development, epithelial cell 
division, and osteoclast maturation (297, 298). SYK function has been linked to several 
disorders including autoimmune diseases, hematological malignancies, rheumatoid 




Figure 1.4 Schematic diagram of SYK structure 
SYK is a protein tyrosine kinase which consists of a C-
terminus catalytic domain to promote activation of 
downstream proteins. It also has two tandem SH2 domains 
at the N-terminal that helps in receptor signaling through 
ITAM binding.  
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As a kinase, SYK phosphorylates multiple proteins on tyrosine to control key receptor 
signaling pathways including Ca
2+
 mobilization and the phosphoinositide 3-kinase 
(PI3K)/AKT, NF-κB and RAS/ extracellular-signal-regulated kinases (ERK) pathways 
(307-313). At least two substrates of Syk, CD79a and the Ikaros protein, also have been 
reported to be phosphorylated by SYK on serine, suggesting that SYK may have 
capabilities beyond catalyzing tyrosine phosphorylation.  Its ability to couple with 
immune recognition receptors makes it an important kinase in the immune system that 
regulates multiple pathways in response to many extracellular signals including antigens 
and immunoglobulin-antigen complexes (314). 
The N-terminus of SYK consists of two 100 amino acid conserved sequences 
known as Src Homology 2 (SH2) domains. These SH2 domains are connected by a 
region known as linker A and both are then separated by linker B from the C-terminal 
kinase domain. These domains bind to proteins containing phosphotyrosine and thus 
initiate protein-protein interactions. The two SH2 domains of SYK bind specifically to 
proteins that contain immunoreceptor tyrosine-based activation motifs (ITAMs). ITAMs 
are characterized by two short peptide sequences of YXXL/I (where Y is tyrosine, L and 
I are leucine and isoleucine, respectively, and X denotes any amino acid) separated by a 
spacer of 6-12 amino acids. Once receptors with ITAMs are oligomerized upon 
engagement, the two tyrosines are rapidly phosphorylated leading to the recruitment and 
activation of SYK (23, 291, 304, 315-317). In some cells, particularly T cells, the SYK-
family kinase ζ-chain-associated protein kinase of 70 kDa (ZAP70) is recruited to 
phosphorylated ITAMs (318, 319).  Following its activation, multiple tyrosines on SYK 
become phosphorylated including sites within the linker A and B regions along with 
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tyrosines within the catalytic domain and at the extreme C-terminus. SYK both 
autophosphorylates and is phosphorylated in trans by LYN.  Examples of important 
phosphorylation sites include Y130 located in linker A, Y317, Y342 and Y346 located in 
linker B, Y519 and Y520 located on the activation loop in the catalytic domain and Y624 
and Y625 near the C-terminus.  Phosphorylations serve to regulate the activity of SYK, to 
modulate kinase-receptor interactions and to promote protein-protein interactions with 
downstream effectors containing SH2 or related domains (304, 320, 321).  
Following its activation, a fraction of SYK is released from the receptor and can 
shuttle between the nucleus and the cytoplasm to promote further downstream signaling 
events. Included among the SYK substrates that have been well characterized are the B 
cell linker protein (BLNK/SLP65), SH2 domain leukocyte-specific phosphoprotein 75 
kDa  (SLP76) , linker for activation of T cells (LAT), PI3K, phospholipase Cɣ (PLCɣ), 
Bruton’s tyrosine kinase (BTK), Vav-1 (Ras/Rho guanine nucleotide exchange factor), β-
tubulin, and CBL (E3 ubiquitin ligase) (322-330).  
 
1.12. Receptor based immune signaling of SYK 
 
1.12.1 Syk in B cell signaling. 
A major component of the adaptive immune response in the body requires B cell 
activation for producing antigen specific antibodies to target foreign molecules and 
pathogens. It is the B cell receptor for antigen (BCR) that recognizes foreign antigens. 
The BCR consists of a membrane-bound immunoglobulin associated with a heterodimer 
of CD79a and CD79b subunits. CD79a and CD79b also are commonly known as Ig-α 
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and Ig-β.  The BCR contains ITAM sequences in the cytoplasmic tails of CD79a and 
CD79b that are initially phosphorylated by a member of the Src-family of protein-
tyrosine kinases. The main Src-family kinase in B cells is LYN, which phosphorylates 
the first tyrosine of the ITAM. The second tyrosine is speculated to be phosphorylated by 
SYK based on in vitro studies. Once both of the ITAM tyrosines are phosphorylated, 
SYK binds tightly through its tandem SH2 domains. Once bound to the BCR, active Syk 
phosphorylates additional ITAM tyrosines leading to additional SYK binding to the BCR 
complex. Activated SYK then catalyzes the phosphorylation of the multiple protein 
substrates that play important roles in antigen receptor signaling to regulate downstream 
cell signaling pathways.  These include for example, the adapter protein BLNK, whose 
phosphorylation creates docking sites for BTK and PLC-ɣ to form a complex ultimately 
facilitating calcium mobilization (315, 331-336).  
1.12.2 Syk in mast cell signaling. 
Mast cells and basophils are key players in inflammation. Their activation results in type 
I allergic reactions through the release of pre-formed inflammatory mediators like 
histamine from cytoplasmic granules and the generation of additional biologically active 
mediators like leukotriences.  Mast cells are enriched with high affinity IgE receptors 
(FcεR1) on their cell surface (23, 291, 317, 337-340).  The stimulation of mast cells is 
initiated by the binding of antigens to FcεR1 receptors pre-associated with IgE. FcεR1 is 
a tetrameric protein consisting of αβɣ2 chains. The Fc region of IgE binds to the α-chain 
of IgE. ITAMs are present in the β- and ɣ- chain, located in their cytoplasmic domains. 
Similar to the BCR, FcεR1 does not have an intrinsic enzymatic activity, but relies on the 
activation of non-receptor protein-tyrosine kinases for its activity (311, 341-343). 
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LYN initiates the phosphorylation of the tyrosines on these ITAMs leading to the 
docking of SYK and its activation.  Active SYK further propagates downstream tyrosine 
phosphorylation of adaptor proteins such as LAT1, LAT2 and SLP76. Several other 
substrates including PI3K, BTK, PLCɣ1, PLCɣ2 and PKC are subsequently activated 
through this pathway. Studies indicate that the absence of SYK in mast cells leads to a 
complete loss of IgE-mediated degranulation and release of cytokines, making SYK a 
key mediator of mast cell signaling and a popular drug target (297, 305, 317, 344, 345). 
1.12.2 Syk in macrophage signaling. 
Macrophages are crucial components of the innate immune response and are the first line 
of defense against pathogens. The most important function of macrophages is to 
recognize foreign substances to either engulf and degrade them or to engage other 
immune cells to destroy them. They are white blood cells of the myeloid lineage and 
differentiate in tissues from circulating monocytes. During inflammation, macrophages 
perform vital functions including phagocytosis, antigen presentation and 
immunomodulation (271, 346-349). The activation of macrophages occurs through 
various stimuli including cell surface components of pathogens such as 
lipopolysaccharide (LPS), cytokines such as interferon-γ and TNF-α, apoptotic cells and 
TH1 T cells. Macrophages express a broad range of receptors including the toll-like and 
dectin-1 pattern recognition receptors, scavenger receptors, and Fcɣ receptors that 
recognize foreign substances and opsonized particles in the body (125, 350, 351). Many 
of these receptors are coupled to downstream signaling pathways through protein kinases 
that, in turn, activate transcription factors such as nuclear factor-κB (NF-κB), activator 
protein-1 (AP-1), and cAMP response element binding protein (CREB) that promote the  
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expression of proinflammatory genes.  Many of these receptors also trigger phagocytosis, 
the secretion of inflammatory mediators, the generation of ROS, the production of nitric 
oxide and the generation of arachidonic acid metabolites such as prostaglandin E2 (PGE2) 
(137, 337, 352-361). 
 Interestingly, many of these receptors in macrophages contain ITAM sequences 
and are thus dependent on SYK for their activities.  These include the Fcɣ receptors, 
which are mainly involved in the phagocytosis of foreign bodies to which IgG is 
associated. These belong to the immunoglobulin gene superfamily. Fcɣ receptors are 
classified into three categories: class I and III, which form multimeric complexes, and 
class II receptors that are monomeric. All Fcɣ receptors contain an extracellular binding 
domain that recognizes the Fc region of IgG. Macrophages primarily express activating 
Fcγ receptors that stimulate phagocytosis and other innate immune responses.  Clustering 
of these receptors leads to the Src-family kinase-mediated phosphorylation of tyrosines 
within ITAMs found either within the receptor or receptor complex. Subsequently SYK 
is recruited to the phosphorylated ITAMs and activated, resulting in the phosphorylation 
of other Fcɣ receptor ITAMs and downstream substrates. FcɣRI, FcɣRIIA, and FcɣRIIIA 
receptors specifically bind to SYK and their clustering leads to its activation. Several 
studies in primary macrophages have revealed that the absence of SYK leads to a failure 
of Fcɣ receptor-mediated phagocytosis and a loss of the receptor stimulated generation of 
NO and ROS, events that are normally enhanced by Fcɣ receptor engagement in 
macrophages (25, 26, 292, 315, 362-364). 
LPS is a commonly used stimulus for macrophages. LPS is found on the surfaces 
of Gram-negative bacteria. Thus, exposure to LPS mimics a bacterial infection. The 
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TLR4 receptor is needed for macrophages to respond to LPS. Interestingly, SYK also is 
activated in macrophages by LPS stimulation. There is evidence that SYK is 
constitutively docked to TLR4 receptors despite the lack of an ITAM. Active Syk thereby 
promotes activation of downstream signaling molecules, such as AKT, PI3K, IKK, NF-
κB and phosphoinositide-dependent kinase-1 (PDK1), ultimately leading to induction of 
TNF-α, COX-2 and inducible nitric oxide synthase (iNOS), and the secretion of nitric 
oxide (NO), ROS and PGE2. Studies also indicate that minimally oxidized low-density 
lipoprotein (mmLDL) activates SYK in macrophages throughTLR4. Activated SYK 
subsequently activates Vav1, PLCɣ and JNK resulting in cytoskeleton modifications, 
ROS generation and cytokine secretion (293, 312, 365-369). 
1.12.4 Syk in neutrophil signaling. 
Neutrophils are also essential cells in the innate immune system. They are the most 
abundant type of white blood cell and also the first cell type to reach a site of 
inflammation. Once in contact with cellular and humoral factors, they become primed 
and travel through blood vessels to the site of microbial infection. Their main function is 
to kill or suppress microorganisms during the innate immune response.  
 Integrin receptors are particularly important receptors in neutrophils and are 
required for cell adhesion, motility, spreading, the respiratory or oxidative burst, release 
of cytokines and release of antimicrobial granule proteins. β1, β2, and β3 integrins in 
neutrophils all associate with SYK to mediate their functions. Neutrophils mainly express 
the β2 integrins αLβ2, αMβ2 and α4β1. Integrin signaling occurs in two steps, known as 
inside-out (integrin activation) and outside-in (aggregation of integrins) signaling. SYK is 
essentially involved on both these signaling pathways.  Studies in SYK negative 
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neutrophils have revealed that, in the absence of SYK, neutrophils fail to spread when 
plated on integrin ligands and fail to undergo respiratory bursts or degranulation in 
response to integrin clustering. Integrins themselves lack ITAM motifs, but in neutrophils 
signal instead through the adaptor proteins DAP12 and FCɣR, both of which contain 




               
Figure 1.5 Schematic diagram of adaptor mediated SYK-
ITAM signaling 
 
SYK is activated through binding of receptor ITAM to SH2 
domains. In receptors like BCR, it requires LYN kinase to 
initially phosphorylate ITAM on receptor adaptor molecule. 
Once activated the receptor further activates through 
autophosphorylation and initiation of SYK-ITAM cascade. 
This activation leads to activation of several downstream 
signaling pathways through tyrosine phosphorylation.  
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Figure 1.6 Schematic diagram of direct ITAM-SYK signaling 
In some rectors like FcɣRIIA, SYK is activated through 
binding of receptor ITAM present at the cytoplasmic tail of 
the receptor. It does not require an adaptor protein for 
activation. LYN kinase initially phosphorylates ITAM on 
receptor tail and SYK binds to phosphorylated ITAM through 




1.13 Syk in the brain 
 
Brain cells can be classified into neuronal and non-neuronal cells. Non-neuronal cells in 
the brain include glial cells and other helper cells that assist with the normal functioning 
of the brain. Glial cells mainly consist of astrocytes, oligodendrocytes and microglia. One 
crucial function of glial cells is to comprise the immune system of the brain, which 
functions quite differently from the rest of the body. The presence of the blood brain 
barrier restricts the ability of normal immune cells in the blood to infiltrate into a healthy 
brain to maintain immunity.  While the brain had long been considered a completely 
immunologically privileged site, interesting new data indicate the presence of a lymphatic 
system that allows T cells access to the meninges (259, 287, 311, 369, 373-375). 
 Although the role of SYK in the brain is poorly understood, considering its vital 
role in the majority of immune cells; SYK’s role in the brain’s immune system cannot be 
neglected.   
 
1.13.1 Syk in neurons 
Few in vitro studies have suggested the presence of SYK in neurons. It has been 
mentioned that SYK is involved in neuronal differentiation in P19 cells (376). Another 
study on the CD3ζ adaptor immune protein in the CNS has suggested that SYK is 
involved in neuronal morphogenesis (377). The presence of an ITAM on CD3ζ allows it 
to bind to the SYK SH2 domains thereby activating SYK. Without SYK, CD3ζ could not 
promote neuronal morphogenesis. Studies on sensory neurons have reported that SYK is 
required for NF-κB activation through the cytokine ciliary neurotrophic factor (CNTF). 
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Upon CNTF stimulation, SYK is activated and phosphorylates IκB leading to NF-κB 
activation. This pathway also promotes neurite growth from developing neurons (313, 
378).   
 
1.13.2 Syk in microglia 
Microglia are the most vital immune cells in the brain. In the CNS, they are mainly 
responsible for phagocytosis of debris, foreign particles, apoptotic cells, and microbes. 
Apart from these activities, they also maintain homeostasis in the brain through the 
secretion of anti-inflammatory and pro-inflammatory factors. Phagocytosis by MG is 
mainly mediated through various receptor types including TLRs, PTRs, PAMPs, RAGE, 
SCARA1, SCARA2, CD36, CD68, integrins and Fcɣ receptors. Many of these immune 
receptors contain ITAMs as discussed above in macrophages (141, 148, 225, 228, 231, 
272, 379-381).  
ITAM-mediated receptor signaling through SYK is crucial for phagocytosis. 
DRAPER, for example, is a phagocytotic receptor in Drosophila that binds to Shark (fruit 
fly version of SYK) and is important for phagocytosis. Both phosphorylation of 
DRAPER ITAM tyrosines and SHARK activation are required for proper phagocytosis 
of damaged axons and debris (259, 382). The homologs of DRAPER in mammals are 
JEDI1 and multiple epidermal growth factor-like domains 10 (MEGF10).  In the 
peripheral nervous system (PNS), 50% of the neurons are eliminated through apoptosis 
during development.  JEDI1 and MEGF10 are essential for glial cell precursors to 
mediate phagocytosis of apoptotic neurons during development. Both contain two ITAMs 
in their intracellular domains that, when phosphorylated, bind to the SH2 domains of 
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SYK.  In the absence of SYK, engulfment of apoptotic neurons is inhibited, but 
phagocytic activity can be recovered when cells are reconstituted with SYK (259). 
DAP12/TYROBP is an adapter protein that contains an ITAM and is important 
for phagocytosis by mammalian MG. DAP12 associates with both TREM2 and signal 
regulatory protein-β1 (SIRPβ1). When phosphorylated following receptor engagement, 
DAP12 associates with SYK to mediate phagocytosis of damaged neurons, demyelinated 
axons and other cellular debris. This involves the binding of the SH2 domains of SYK to 
the phosphorylated ITAM of DAP12. TREM2 is important for the uptake of apoptotic 
neuronal cells.  Additional studies suggest that TREM2 also binds to lipo-
oligosaccharides of both Gram-positive and -negative bacteria. Binding stimulates 
TREM2 and, via ITAM and SYK-dependent signaling, promotes phagocytosis of bacteria. 
Interestingly, certain heterozygous mutations in TREM2 are correlated with enhanced 
incidence of AD. Furthermore, DAP12 was identified recently as a key regulator of genes 
associated with late-onset AD (18, 21, 231, 254, 287, 383, 384). 
Immunoreceptor tyrosine based inhibition motifs (ITIMs) resemble one-half of an 
ITAM.  Receptors bearing ITIMs negatively regulate phagocytosis. ITIMs inhibit ITAM-
mediated signaling by recruiting the SH2 domain-bearing protein tyrosine phosphate 
SHP1 and the lipid phosphatase SHIP1 to counteract the activation of protein and lipid 
kinases that occurs during ITAM-mediated signaling (21, 385).  CD33 related sialic acid-
binding immunoglobulin superfamily lectins (SIGLECS) are examples of proteins 
bearing ITIMs. They belong to the Ig superfamily and recognize specific sugar residues 
on cell surface glycans. Since they contain an ITIM sequence in their cytoplasmic 
domains, they negatively regulate ITAM-SYK receptor signaling in MG. Interestingly, 
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CD33 expression is enhanced in AD brains and has been linked genetically to AD in 
GWAS studies (20, 288, 289, 386).   
 Another group of receptors that play a vital role in the phagocytotic ability of MG 
are Fcɣ receptors. As discussed above, many of these contain ITAMs and thus require 
ITAM-SYK mediated signaling for engulfment of opsonized particles. Clustering of Fcɣ 
receptors initiates ITAM phosphorylation, which in turn docks SYK through its SH2 
domains. This ITAM-SYK interaction further activates SYK and hence activates 
downstream signaling pathways to facilitate phagocytosis of opsonized particles and 
antigens (9, 273, 387-389).   
 DECTIN-1, a major beta-glucan receptor that promotes phagocytosis of fungal 
pathogens, also is associated with SYK in MG. DECTIN-1 is unusual in that it’s 
cytoplasmic tail contains only one-half of an ITAM (known as a hemITAM). DECTIN-1 
is thought to function as a dimer whereby two DECTIN-1 molecules bind simultaneously 
to a single SYK molecule to promote its activation (223).   
Several studies have revealed that SYK is essential not only for phagocytosis by 
MG, but also for cytokine production, NO synthesis and ROS generation. SYK mediates 
IL-1β and TNF-α secretion in MG through activation of NF-κB.  The secretion of these 
cytokines into culture media can promote apoptosis of co-cultured adult neurons. β-
amyloid fibrils or prion protein aggregates can activate SYK in MG cells. This activation 
is accompanied by intracellular calcium release and PKC activation leading to the 





1.14. Stress granules and their components 
 
SGs are cytoplasmic RNA-protein complexes that appear in eukaryotic cells in response 
to various kinds of stress-related stimuli that impair translation.  Some of these stressors 
include heat, viral infection, oxidative stress, ultraviolet irradiation, and hypoxia. SGs 
were first identified in cells cultured at high temperature, which led to the formation of 
cytoplasmic granules containing heat shock proteins. The phosphorylation of eukaryotic 
translation initiation factor 2-alpha (eIF2α) is one of the initial steps in SG assembly 
induced by stress. Based on the stress stimulus, distinct eIF2α kinases can be activated 
((protein kinase R (PKR), protein kinase RNA-like endoplasmic reticulum kinase 
(PERK), Heme-regulated eIF2α kinase (HRI) and general control nonderepressible 
2( GCN2)) (390-392).  The subsequent phosphorylation of eIF2α stalls assembly of 
ribosomes at the 48S pre-initiation complex. As a result, this initiation complex remains 
assembled at the 5’ end of mRNAs resulting in translation impairment and a block in 
polysome assembly. These nonpolysomal transcripts are then aggregated into complexes 
along with many other RNA binding proteins to form SGs (393, 394). 
Since their discovery, numerous studies have shown that SGs contain many 
biological components important for mRNA metabolism.  The major components include 
nontranslating mRNAs, translation initiation complexes, RNA binding proteins, mRNA 
processing helper proteins, aggregated proteins, kinases and other proteins involved in 
stress signaling. Some of the major proteins involved in SG formation are: AU rich 
element binding proteins, Argonaute, eIF2α, fragile X mental retardation protein (FMRP), 
fragile X mental retardation related protein 1 (FXR1), Ras-GTPase-activating protein 
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SH3-domain-binding protein (G3BP), glycine-tryptophan 182 (GW182), poly(A)-binding 
protein 1 (PABP1), T cell internal antigen-1 (TIA-1) and T cell internal antigen-1-related 
(TIAR) (395-398). 
Recent studies have shown that many proteins responsible for RNA splicing, 
transcription, adhesion, immune signaling, autophagy and apoptosis also associate with 
SGs.  The function of SG formation in various biological systems or conditions is yet to 
be completely deciphered. Studies suggest sequestration of mRNAs in SGs is a way to 
protect them from stress and conserve energy to overcome stress. SG are highly dynamic 
in nature and self-assemble and disassemble based on changes in the environment of the 
cell (28, 399).  
1.14.1 SG assembly and disassembly 
The presence of diverse proteins, RNAs and other biological molecules suggest that SG 
assembly is very dynamic and variable depending on the biological system on the type of 
stress induced. In some instances, composition of SGs depends on the type of mRNPs 
present in the SG at that specific stress stimulation. Since specific isolation of SGs has 
not been possible yet, most of the studies on SG are done through microscopy or 
correlated to the function of SG components under stress conditions. Such studies have 
reported that the size and shape of SG can vary in different systems. It also mentions that 
SGs do not confer to a definite structural organization (398, 400-403). 
 SG assembly is mainly modulated by three factors: covalent protein modifications, 
protein-protein interactions and microtubule network dynamics.  In terms of protein 
modifications, a key process is phosphorylation.  As described above, eIF2α 
phosphorylation is one of the most crucial steps in SG assembly. Other proteins that 
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undergo phosphorylation during SG assembly are TRISTETRAPROLIN (TTP), B-
related factor 1 (BRF1) and Ras-GTPase-activating protein SH3-domain-binding protein 
(G3BP). In addition, the acetylation of histone deacetylase 6 (HDAC6) also has been 
reported to affect SG assembly as has protein methylation and methyl group binding to 
proteins with Tudor domains.  One study also mentioned the role of ubiquitin-dependent 
proteasome system (UPS) in SG assembly. UPS interference modulates mRNA decay. It 
promotes phosphorylation of eIF2α and sequestration of AU-binding proteins (AUB) and 
ARE in SGs thereby preventing their decay under stress (15, 27, 398, 404). 
Recent studies have shown that protein-protein interactions are critical for SG 
assembly. Many RNA-binding proteins like G3BP contain dimerization domains that 
promote protein-protein interactions that aid in SG formation. In fact, the overexpression 
of G3BP alone is sufficient to induce SGs.  Additionally, RNA metabolism helper 
proteins like TIA-1 that contain QN-rich prion-like domains also participate in SG 
assembly through self-aggregation.  Examples include the prion-like proteins TIA-1 and 
TIAR, which accumulate in the cytoplasm as complexes under SA or MG132 mediated 
stress promoting SG assembly. Proteins susceptible to unfolding or misfolding ((TAR 
DNA-binding protein 43 (TDP-43), Fused in Sarcoma (FUS) and TAU)) observed in 
several diseases like ALS and AD also bind to each other along with other RNPs to 
promote SG assembly. A third important factor that contributes to SG assembly is the 
microtubule network. Microtubules associated motor proteins like dynein and kinesin 
also associate with SGs and regulate their assembly and disassembly (398, 405-407).   
SGs disassemble following removal of the stress. Stress removal repairs the translation 
initiation machinery and helps SG components to disassociate to allow mRNAs to resume 
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translation or to be transferred to processing bodies for degradation. Heat shock proteins 
that disaggregate prion like-proteins have been correlated with SG disassembly. The 
RNA-binding protein Staufen1 (STAU1) has been associated with SG dynamics. The 
overexpression of STAU1 promotes SG disassembly whereas knockdown promotes 
assembly. Studies suggest that STAU1 promotes the stabilization of the mRNA-
polysome complex during this process (408).  Another study showed that, upon stress 
removal, FAK promotes the phosphorylation of growth factor receptor-bound protein 7 
(GRB7) to weaken its interactions with SG component proteins like TIA-1, leading to SG 
disassembly (409). 
Autophagy has been recently linked to SG removal. It has been shown that SG 
clearance is reduced in eukaryotic cells by inhibition of autophagy or depletion of 
proteins like valosin-containing protein (VCP) and autophagy related protein (ATG) 
which is required for autophagy machinery in cells (32). 
1.14.2 SG components 
Depending on the cell type, stress induced and biological system under study, the 
components of SG can vary. The first class of SG components represents members of 
translation initiation complexes. Major proteins in this category include eIF2α, eIF3, 
eIF4F, eIF4B, components of small ribosomal units and PABP-1. These are considered 
core components of SGs. The second class of components are the mRNA binding 
proteins, translation modifying proteins and proteins involved in mRNA stability. Few 
examples of such proteins are TIA-1, TIAR, FMRP, FXR1, FAST, ARGONAUTE, 
cytoplasmic polyadenylation element binding protein (CPEB), ATAXIN-2, and RNA-
associated protein 55 (RAP55). Proteins involved in RNA decay that are SG components 
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include TTP, BRF1, receptor for Activated C Kinase 1 (RACK1), Z-DNA Binding 
Protein 1 (ZBP1) and PMR1 (27, 28, 394, 406, 410). 
  Finally, the third class of SG components consists of RNA binding protein that 
controls RNA decay and processing.  In this category we have G3BP, CAPRIN, FAST, 
survival of motor neuron (SMN) and Ins (1,3,4,5,6)P5 2-kinase (IP5K).  Few of these SG 
components like TIA-1, G3BP can be a part of both second and third class. Recent 
studies have shown that some proteins that do not directly interact with RNA, interact 
instead with core SG components to become a part of a SG. For example, steroid receptor 
coactivator-3 (SRC-3), TAU, folate-binding protein (FBP) proteins are found in SGs 
because of their ability to interact with TIA-1; TNF Receptor-Associated Factor 2 
(TRAF2) on the other hand binds to eIF4G and DIS1 binds to eIF3 (29, 411-413).  
1.14.3 SG functions 
The true function of SGs in the cell is not totally clear. Studies indicate that SGs are 
present in very different biological systems and participate in multiple processes. SG 
components have roles in biological functions like mRNA stability, mRNA translation 
and mRNA modification outside of their localization in SGs. Hence knockdown studies 
of SG components do not directly address the function of SGs.  One of the major 
suggested consequences of SG formation is to regulate mRNA stability. Formation of 
SGs containing untranslated mRNAs under stress protects them from degradation in the 
cytoplasm. Once the stress is gone and SG disassembly occurs, these mRNAs are freed to 
participate normally in translation. Since SGs consist of mRNP complexes including 
translation initiation complexes the formation of SGs under stress may assemble and 
store specific mRNP proteins for participation in future translation processes. Since under 
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stress translation is stalled, excess mRNPs required for translation are stored as SGs 
which are later utilized once the stress is gone (398, 404, 414-416). 
Under stress, a cell ultimately needs to decide if it will be able to recover from the stress 
or, if the stress is too extreme, to undergo apoptosis through programmed cell death. SGs 
play important roles in the apoptosis of cells under stress. For example, MAP kinase 
kinase kinase (MTK1) is activated in cells under severe stress. MTK1 activation-
mediated apoptosis takes place through an interaction with receptor for activated C kinase 
1 (RACK1). In vitro studies have shown that, under stress, RACK1 is sequestered to SGs, 




Figure 1.7 Schematic diagram of stress granules in 
neurodegeneration 
 
In neurodegerative diseases like AD, ALS and SMA, presence of 
SGs have been reported in human brain and animals models. Core 
SG components like G3BP1, TIA-1 associate with misfolded and 
aggregated proteins like TAU, TDP-43 in neurons. The size and 
number of stress granules increases with the disease progression. 





1.15. Stress granules in different neurological diseases 
 
1.15.1 SGs in Alzheimer’s disease 
 AD is a progressive neurological disorder. As mentioned earlier, oxidative stress is one 
the key players in AD. Protein misfolding and accumulation of tau proteins and Aβ is a 
common event in AD. As a consequence, chronic neuroinflammation and neuronal cell 
death is observed. Studies have suggested that SG components like TIA-1, TTP and 
G3BP associate with pathogenic tau epitopes. TIA-1 positively regulates apoptotic cell 
death and regulates mRNA translation of TNF-α and COX-2.  TTP on the other hand 
associates with mRNA for TNF-α, GM-CSF, COX-2, IL-3, IL-10, and interferon-ɣ 
making it an important protein in inflammatory pathways (29, 419, 420). 
1.15.2 SGs in Amyotropic Lateral Sclerosis (ALS) 
ALS is a neurodegenrative disease that mainly affects the motor neurons. It is considered 
the most common motor neuron disease. The neuronal death mainly takes place at the 
brain stem, spinal cord and motor cortex. As a result of such degeneration, muscle 
fasciculation, wasting and weakness; increased spasticity, and hyperreflexia are observed. 
One of the hallmark proteins involved in ALS is TDP-43. In ALS patients, TDP-43 is 
mutated, mis-folded and aggregated in degenerating motor neurons. Recent studies have 
shown that TDP-43 is localized in SGs in ALS. Another disease that is closely linked 
with ALS is Frontotemporal Lobar Degeneration (FTLD). TDP-43 is also mutated in 
FTLD. TDP-43 is mainly a nuclear protein, but in neurodegerative diseases it is mis-
localized to the cytoplasm. TDP-43 plays an important role in mRNA metabolism. In 
neurons, it mediates splicing and mRNA stability. Hence it influences proteins that are 
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required for proper formation of synapses in neurons. Since TDP-43 is localized to 
cytoplasmic SGs in ALS, it cannot further maintain mRNA stability. On the other hand, 
TDP-43 has a self aggregating domain and an excess of TDP-43 promotes aggregation. 
Such aggregation of TDP-43 in turn elevates its expression. Excess TDP-43 has been 
reported as neurotoxic to neurons and promotes apoptosis. TDP-43 tightly binds to G3BP 
in neurons. This binding promotes self aggregation of TDP-43 leading to larger SGs. 
Other proteins that localize to SGs in ALS are FUS, HUNTINGTIN and PrP (38, 405, 
406, 421-423).   
1.15.3 SG in spinal muscular atrophy 
SMA is a recessive neuromuscular disorder that affects the α-motor neurons. It mainly 
occurs in infants and involves the spinal cord. Mutations in or deletions of the telomeric 
copy of the SMN-1 gene and retention of the telomeric copy of SMN-2 characterizes this 
disease. SMN plays a key role in axonal growth and maintenance through regulation of 
mRNA metabolism. SMN has been reported to be localized in SGs. SMN localization in 







CHAPTER TWO: MATERIAL AND METHODS 
 
2.1 Cells and cell lines 
 
BV-2 microglial cells developed by Blasi and colleagues (387) were obtained from Dr. 
Chris Rochet (Purdue University) and cultured in high glucose DMEM media containing 
10% FBS and 100 U/ml penicillin and streptomycin. The cells were passaged at a ratio of 
1:8 every 48 h and a confluency of 60-80% was maintained at all times. Fresh cells were 
passaged at least two times before conducting an experiment.  The use of freshly thawed 
cells was limited to 12 passages.   
  N9 microglial cells
 (426) 
were obtained from Dr. Fabio Bianco (Neuro-Zone, Italy) 
and were cultured in ISCOVE medium containing 10% FBS and 100 U/ml penicillin and 
streptomycin. Cells were passaged at a ratio of 1:6 every other day to obtain consistent 
results. The confluency of these cells was maintained at 50-70 % at all times. Freshly 
thawed cells were were used for a maximum of 15 passages. 
HEK293T cells were purchased from ATCC and HT22 mouse hippocampal neuronal 
cells
58
 were obtained from Dr. Shaohua Yang, (University of North Texas Health 
Sciences Center).  Both were grown in DMEM containing 10% FBS and 100 U/ml 
penicillin and 100 mg/ml streptomycin. All cell lines were grown at 37
o






2.2 Plasmids and Lentiviral vectors 
 
The cDNA coding for mouse Syk-EGFP fusion protein was cloned into a puromycin 
resistance lentiviral vector pLVX as described (427). Lentivirus particles were generated 
by cotransfecting HEK293T cells (2 X10
6
 cells/10 cm plate) with 5 µg of Syk-EGFP 
pLVX, 5µg of pHR’ CMV-R8.20 VPR and 2.25 µg of pHR’ CMV-VSVG using 
Lipofectamine 200 (Invitrogen). After 48 h the media supernatant containing viral 
particles was collected and filtered using 40 µm pore size filter. Harvested lentiviral 
particles were added to BV-2 cells (2 X10
5
 cells/10 cm plate) in the presence of 10 µg/ml 
polybrene. 48 h post infection, cells were selected in the presence of 5 µg/ml puromycin 
for 92 h. Finally, cells were maintained in 2.5 µg/ml puromycin and passaged every 48 h.  
To establish the mouse Syk knockdown BV-2 cell line, BV-2 cells (2 X10
5
 
cells/10 cm plate) were infected with one of a set of six independent GIPZ mouse Syk 
shRNA lentiviruses (GE Dharmacon). A scrambled shRNA was also infected to establish 
a control cell line. Six independent Syk shRNA and scrambled shRNA lentiviral particles 
were generated as described above with the lentiviral vectors for Syk-EGFP. 
Lipofectamine 3000 (Invitrogen) was used instead of Lipofectamine 2000 to transfect 
HEK293T cells. One of the plasmids among the six exhibited robust knockdown as 








2.3 Primary cell culture and animal models 
 
Primary microglial cells were isolated essentially as described
 
(428, 429) from 1 month 
or 20 month old wild-type or Syk
+/-
 C57BL/6 mice.  Syk-haplosufficient mice were 
generated by gene targeting by Ingenious Targeting Laboratory, Ronkonkoma, NY.  
Approximately, 5 mice from each group were anesthetized using isoflurane 
anaesthetizing equipment and perfused in the left ventricle at constant pressure for 5 min 
with ice cold Ringer’s solution containing 2 U/ml heparin (Cat. No. AK3004, Akron 
Biotech, USA). Immediately brains were aseptically removed and meninges separated. 
The brain was minced and dissociated with a sterile scalpel blade in media containing 1 
mg/ml papain, 1.2 U/ml dispase II (Cat. No. P4762 and D4693, Sigma-Aldrich, USA) 
and 20 U/ml DNase1 (Cat. No AK3778, Akron Biotech, USA). Following pH 
neutralization of media, cells were pelleted and recovered, pipetted up and down using 
glass Pasteur pipettes of decreasing hole sizes, filtered through 70 µm and 40 µm cell 
strainers and collected in media. Cells were separated on a discontinuous percoll (Cat. No. 
17-0891-01, GE Healthcare, USA) density gradient, collected, washed, and cultured on 
1μg/cm2 fibronectin (Cat. 341631, Calbiochem)-coated dishes.  Three different 
concentrations (70% SIP, 37% SIP and 30% SIP) of saturated isotonic percoll (SIP) were 
used and microglia were present between 37% and 70% SIP. Isolated cells were washed 
and cultured in DMEM containing 5 ng/ml murine carrier free granulocyte and 
macrophage colony stimulating factor (GM-CSF) (Cat. No. 130-094-043, Miltenyl 
Biotech), 10% FBS and 100 U/ml penicillin and 100 mg/ml streptomycin. For 
experiments, 1 X10
3





containing 10% FBS and 100 U/ml penicillin and 100 mg/ml streptomycin.  Primary 
microglia were confirmed by western blotting and immunofluorescence staining of IBA1 
(428).  All mice were housed and experiments were done in accordance to the guidelines 
of IACUC at Purdue University. 
 
2.4 Stress granule formation 
 
BV-2 or N9 cells (1 X10
4
 cells/well in a 24 well plate) were grown on poly-D-lysine 
coated cover slips in media containing 1% FBS for 12 h before treatment with sodium 
arsenite (SA) (1 µM), Aβ(1-42) (100 nM), or Aβ(1-42) fibrils (100 nM) for the indicated 
times. Aβ(1-42) (rPeptide, Cat. No. A-1008) or Aβ(42-1) (American Peptide Company, 
Cat. No. 62-0-81) were resuspended in DMSO, 1% NH4OH at a concentration of 0.025 
M. To prepare Aβ fibrils, DMSO soluble Aβ was sonicated  for 30 min at 1 min intervals, 
shaken at 37
o
C for 48 h and then at room temperature for 72 h (59, 430).  Treated cells 
were fixed in 4% formaldehyde in PBS, permeabilized in 1% Triton X-100, blocked with 
5% goat or donkey serum (depending on the species of origin of the secondary antibody) 
and incubated overnight at 4
o
C with primary antibody diluted at a ratio of 1:1000 in 5% 
goat or donkey serum in PBS.  Secondary antibodies Alexa Fluor 488 or 594 against 
mouse, rabbit, goat and donkey species were purchased from Life Technologies. Nuclei 
were visualized by staining with Hoechst 33342 (Sigma-Aldrich). Coverslips were 
mounted with ProLong® Gold Antifade reagent (Life Technologies) and examined using 
a Zeiss LSM 710 confocal microscope. Five 25X frames (average of 75 cells each frame) 





SGs were selected, and corrected total cell fluorescence (CTCF) was calculated using 
ImageJ. CTCF was used to measure the SG area in arbitrary units also known as 
brightness values. The number of SGs was manually calculated from five random 63X 
frames (average of 25 cells each frame) from three independent experiments using Zeiss 
2012 software. All statistical calculations were done using GraphPad Prism 6 and one 
way ANOVA statistical test was performed to calculate the P-value. Error bars in the 
figures represent means ± SEM. 
 
2.5 Western blotting and immunoprecipitation assays 
 
For general immunoblotting experiments, N9, BV-2 or primary microglial cells were 
lysed in buffer containing 1% NP-40, 50 mM Tris/HCl, pH 8.0, 150 mM NaCl, 5X 
protease inhibitor cocktail (13911, Sigma-Aldrich), 10 µM sodium orthovandate for 15 
min on ice. After centrifugation at 14000 X g for 10 min, supernatants were collected, 
separated by SDS-PAGE and analyzed by western blotting. To prepare soluble and 
insoluble fractions, cells were lysed in buffer A (15 mM Tris-HCl, pH 7.6, 0.3 M NaCl, 
15 mM MgCl2, 1% Triton X-100, 10 mM Ribonucleoside Vanadyl Complex (Cat. No. 
S1420S, New England Biolabs), 5X protease inhibitor cocktail and 10 µM sodium 
orthovanadate) on ice for 10 min. Cells were disrupted by mortar and pestle (20 times 
moved up and down). The insoluble fraction was isolated by centrifugation at 1500 X g 
for 7 min and the supernatant was collected as the soluble fraction. The insoluble fraction 
was dissolved in SDS-sample buffer (1% SDS in 1X NP-40 lysis buffer). Further 





Finally western blotting was performed to quantify the protein levels.  For 
phosphotyrosine immunoprecipitation assays, whole cell lysates prepared in buffer A 
were incubated with anti-phosphotyrosine (4G10, EMD Millipore)-coated protein G 
magnetic beads (Cat. No. P3296, Sigma-Aldrich) for 2 h at 4
o
C. Beads were washed 
thrice with 1X NP-40 lysis buffer, once with 1X high salt solution and once with double-
distilled water. Finally, bound proteins were eluted with SDS-sample buffer. Immune 
complexes were examined by western blotting to identify associated proteins.  
 GFP-TRAP immunoprecipitation assays were conducted to isolate the GFP-fusion 
protein from Syk-EGFP-expressing BV-2 cells. Whole cell lysates were prepared in 
buffer A. A nucleus-enriched portion was separated by centrifuging at 5000 X g for 7 min 
at 4
o
C.  Supernatant was collected and incubated with GFP-TRAP beads (Cat. No. gta-20, 
ChromoTek Inc. USA) for 30 min at 4
o
C. Beads were washed as described above and 
subjected to western blotting for further analysis.   
 
2.6 Microglial cell functional assays 
 
Phagocytic activity of N9 and BV-2 cells (1 X10
4
 cells/ plate) was assessed by the uptake 
of pHrodo
TM
 Red E. coli BioParticles® (Cat. No.P35361, Life Technologies). N9 and 
BV-2 cells were grown in poly-D-lysine coated glass bottom dishes (MatTek, P35G-1.5-
10-C, MatTek Corporation, USA) for 12 h in growth media containing 1% FBS and then 
treated as indicated for 120 h. Subsequently media was removed. Cells were washed 
twice with 1X PBS buffer and incubated in 2 ml Live Cell Imaging Solution (Cat. no. 





was obtained thereafter in 5% CO2 and 37
0
C on a confocal microscope (Zeiss LSM 710) 
stage for another hour. Hoechst dye was added to visualize the nucleus.  Live images of 
cells were taken at 30 sec intervals and compiled into a movie.  For fixed cell images, 
cells were incubated for 1 h in 2 ml Live Cell Imaging Solution containing 100 μl 
pHrodo
TM
 particles; fixed and examined by confocal microscopy. Phagocytosis of 
fluorescent red particles was quantified by measuring the mean corrected fluorescence 
intensity using ImageJ software from five random equal sized frames for each treatment 
condition.  
The phagocytosis of FITC-labeled Aβ fibrils (rPeptide, Cat. No. A-1119-1) was 
measured using N9 cells in a similar manner except cells were incubated for 1 h with 25 
µl FITC-labeled Aβ fibrils (fibrils prepared from 0.25 M solution of soluble Aβ(1-42)). 
Cells were washed extensively, fixed and imaged by confocal microscopy as mentioned 
above.   
Intracellular ROS production was measured using both the 5(6)-carboxy-2',7'-
dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) (Cat. No. 6982, Setareh 
Biotech) and dihydrorhodamine 123 (D123) (Cat. No. D-23806, Life Technologies) 
reagents. N9 cells were grown in 96-well plates in media containing 1% FBS and treated 
as indicated with SA or Aβ(1-42) in the presence or absence of 500 nM Syk kinase 
inhibitor (R406  or PRT-060318 (Selleckchem)) for 120 h. Carboxy-H2DCFDA (10 µM) 
was added and incubated at 37
o
C for 1 h.  Cells were washed 3 times with 1X PBS. 
Fluorescence was measured using a microplate reader (Biotek Synergy 4). Alternatively, 
treated and control cells were incubated with D123 (5 µM) for 1 h. Cells were stained 





Quantitative analyses used ImageJ to measure mean fluorescence intensity. The area 
enclosing the green fluorescent signal (background signal subtracted) was measured in 5 
random frames from three independent experiments.  
Extracellular production of H2O2 was measured using Acridan Lumigen PS-3 
reagents (Amersham ECL kit) as described (433). ALPS-3 substrate was prepared by 
mixing Reagent A (H2O2, Amersham ECL kit) with Reagent B (Acridan solution, 
Amersham ECL kit) in a ratio of 10:1. N9 cells grown in media containing 1% FBS were 
plated on 1% poly-D-lysine coated 24 well plates and treated with SA, Aβ (1-42) and/or 
Syk inhibitors for 120 h. 50 μl of media from each well was transferred to another 96 
well plate and 50 μl of fresh ALPS-3 substrate was added. The plate was stored in the 
dark for 10 min at room temperature. Chemiluminescence was detected using a 
luminescence plate reader (Glomax, Promega) at 430 nm.  
To measure reactive nitrogen species, N9 cells were grown and treated as 
mentioned above. Media was collected and reactive nitrogen species quantified by 
measuring nitrite levels using the Measure-iT™ High-Sensitivity Nitrite Assay Kit (Cat. 
No. M36051, Life technologies). In a black opaque clear bottom 96 well microplate 
(Corning, USA), 100 μl of quantitation reagent was incubated with 10 μl of media from 
each well containing cells (post-treatment). After incubation for 10 min, 5 μl of the 
developing reagent was added and fluorescence was measured using a microplate reader 
(excitation/emission 365/450 nm, (Biotek Synergy 4)). A standard curve was plotted 
using the standards provided with the kit.  
 





N9 microglial cells (5 X10
3
 cells/well) plated in poly-D-lysine-coated 24-well plates 
were treated as indicated with SA, Aβ and/or Syk inhibitor for 120 h. Cells were gently 
detached and washed with PBS. 5 X10
2 
cells from each treatment condition were added 
to an 8 µm pore size transwell insert (Thincert
TM, 
Greiner bio-one) and placed atop 1.5 X 
10
4
 HT22 cells plated in DMEM media without phenol red containing 1% FBS and 100 
U/ml penicillin and 100 mg/ml streptomycin. Co-cultured cells were incubated for 48 h. 
After 48 h, HT22 cells were washed with PBS and incubated with FITC Annexin V (Cat. 
No. 556420, BD Biosciences) for 30 min at 37
o
C. Finally cells were fixed, stained with 
Hoechst dye and examined by confocal microscopy. 
 
2.8 Human AD clinical samples 
 
Paraffin-fixed human AD brain and normal brain cortex samples were obtained from the 
Brain and Body Donation Program, Banner Sun Health Research Institute, Arizona
64
. 
Samples were clinically evaluated based on several criteria including mini-mental state 
examination (MMSE) score, plaque density, lewy body prevalence and dementia. 
Paraffin fixed cortex brain slices were heated at 65
0
C for 30 min, fixed with 4% 
paraformaldehyde, washed sequentially with different concentrations of ethanol (70%, 
50%, 30%) and then subjected to antigen retrieval by heating in 10 mM Tris/HCl (pH 10) 
for 20 min at 85
0
C. Slides were blocked with 5% donkey serum and 2% BSA overnight 
at 4
0
C. Brain slices were stained using primary antibodies against SYK, IBA1, G3BP and 
phosphotyrosine overnight at 4
o
C. On the following day, slides were washed 5 times with 





H-5501, Vector Labs) and examined using a Zeiss 710 LSM confocal microscope. The 
area enclosed by SG in brain slides was measured using ImageJ as mentioned earlier for 




The antibodies and sources used in this study were as follows: Syk (D3Z1E, Cell 
Signaling Technology or B01P, Abnova), G3BP1 (611126, BD Biosciences or 07-1801, 
EMD Millipore), pEIF2α (E90, Abcam), TIA-1(ab2712, Abcam), PABP1 (ab21060, 
Abcam), GFP (168AT1211, Abgent), GAPDH (6C5, Ambion), pTYR (4G10, EMD 
Millipore), IBA1 (ab5076, Abcam), GFAP (GF5, Abcam), TDP-43 (10782-2-AP, 
Proteintech), NOS2 (ab3523, Abcam), Integrin β1 (4B7R, Santa Cruz Biotech), CD32 








CHAPTER THREE: RESULTS 
 
3.1. SYK is highly expressed in BV-2 and N9 microglia cell 
 
A few studies have suggested that SYK is present in microglial cells, but none of these 
compared the expression levels of SYK to those of other immune cells. Endogenous SYK 
protein level had not been examined previously in N9 cells. Hence, I first wanted to 
confirm the expression level of SYK in two well- known immortalized microglial cell 
lines: BV-2 and N9. Cells were grown for 24 h in complete media and lysed in 1X NP-40 
lysis buffer. Immunoblotting for endogenous SYK revealed a high level of expression of 
SYK in both lines as shown in comparison to DG75 B cells (Fig. 3.1). It has been 






























Figure 3.1 SYK expression was examined in the DG75, B cell-line, and the 
BV-2 and N9 microglial cell lines. Cell lysates were analyzed by western 
blotting with SYK and GAPDH antibodies. GAPDH was detected as a loading 
control. 





3.2 Low dose of sodium arsenite promotes SG formation in microglial cells 
 
Environmental stress induces SG formation in eukaryotic cells. One of the classical SG 
inducers is sodium arsenite (SA). To determine if SGs form in these MG, I first treated 
BV-2 and N9 cells with sodium arsenite for 24 h. Numerous SGs were found in both cell 
lines when treated with low concentrations of SA (1 μM) for 24 h as revealed by the 
appearance of puncta that stained with the SG marker G3BP1 (Fig. 3.2). Next I wanted to 
examine if SYK localized to these SGs. To determine that, I treated both MG as 
described above in Fig.3.2, and fixed and stained cells with an antibody against the 
kinase. A fraction of SYK co-localized with G3BP1 in SGs in both cell types when 
treated with SA (Fig. 3.2). The concentration of SA that was required to induce SGs was 
surprisingly low compared to the level commonly (250/500 µM) used to induce SGs in 






































Figure 3.2 SG formation in BV-2 and N9 cells was examined under SA 
treatment. BV-2 and N9 cells were treated with SA (1 μM) for 24 h. On the 
following day, cells were fixed and stained for endogenous SYK (green) and 
G3BP1 (red). Confocal images were obtained using a Zeiss LSM 710 
microscope. White arrows indicate SYK and G3BP1 co-localized SGs. Scale = 
10 m. 
 







3.3 Soluble amyloid beta induces SG formation in MG 
 
Recent reports have shown that misfolded or aggregated proteins like TAU, TDP-43 and 
PrP can induce SG formation in neuronal cells (38, 436, 437). Neurodegenerative disease 
animal models have also confirmed the presence of misfolded proteins associated in SGs 
in neuronal cells. It is hypothesized that stressors in neurogeneration can induce such SGs. 
I then asked if exposure to a stressor implicated in neurodegeneration might also lead to 
SG formation in MG. Abundant SYK-positive SGs were induced in both BV-2 and N9 
cells treated with 100 nM soluble Aβ(1-42) for 24 h (Fig. 3.3A). Quantitative analyses of 
SYK and G3BP1 co-localized SG punctas were made for BV- 2 cells using ImageJ. 
Analyses revealed a five-fold increase in area containing SYK and G3BP1 positive SG in 
cells treated with SA or Aβ(1-42) compared to control (Fig. 3.3B). As a control, BV-2 
cells also were treated with soluble Aβ(42-1).  Aβ(42-1) treatment did not form SGs in 






































Figure 3.3. (A) BV-2 and N9 cells were treated without (Control) or with Aβ for 24 h, fixed and stained 
for SYK (green) and G3BP1 (red). Examples of SGs are indicated by the arrows. (B) The area 
occupied by SYK and G3BP1 positive SGs in N9 cells was quantified by Image J analysis of 5 
random frames from 3 independent experiments. Results represent means ± SEM. *P = 0.001. (C) 
BV- -1) as a control for 24 h, fixed and stained for SYK (green) 
and G3BP1 (red). Only merged images are shown. Bar = 10 µm.   










3.4 SYK and G3BP1 co-localizes with other SG core components in BV-2 and N9 
cells 
 
SGs are extremely dynamic and varied in terms of their components. Various translation 
initiating factors, mRNA-binding proteins and some other proteins that associate with SG 
core proteins form the major components of SGs. Depending on the biological system, 
cell line and stress type, different SG components have been reported. I then asked if 
other proteins commonly found in SGs were present within these complexes in MG. BV2 
cells were treated with SA or Aβ for 24 h, fixed and stained for SYK and co-stained for 
phosphorylated EIF2α, PABP1, TDP-43 or TIA-1. SYK-positive puncta produced by 
both stimuli contained each of these proteins (Fig. 3.4A). Similar results were observed in 
N9 cells under similar treatment conditions (Fig. 3.4B). G3BP1 also co-localized in 
puncta with pEIF2α, TDP-43 and TIA-1 in N9 cells treated with SA or Aβ (Fig. 3.5).  
Since SGs are insoluble in mild detergents, I fractionated control and stressed MG 
into detergent-soluble and insoluble fractions and immunoblotted each for SYK, G3BP1, 
pEIF2α and TIA-1. A significant increase in the presence of SYK, G3BP1, pEIF2α and 
TIA-1 in the detergent-insoluble fractions accompanied treatment of both N9 and BV-2 


























Figure 3.4 SYK co-localizes with pEIF2α, TDP-43, PABP1 and TIA-1 in BV-2 
and N9 cells 
Figure 3.4. BV-2 (A) and N9 (B) cells were treated without (Control) or 
with SA or soluble Aβ for 24 h, fixed and stained for SYK, pEIF2α, 
PABP1, TDP-43, TIA-1 and/or G3BP1 as indicated. Only merged images 































Figure 3.5. G3BP1 co-localizes with pEIF2α, TDP-43, PABP1 and TIA-1 in  
BV-2 and N9 cells 
 
Figure 3.5. N9 cells were treated without (Control) or with SA or soluble A for 24 h, 
fixed and stained for G3BP1, pEIF2, TDP-43 and  TIA-1. Only merged images are 











Figure 3.6 N9 (A) and BV-2 (B) cells were treated without (-) or with (+) SA or soluble 
Aβ for 24 h and then separated into detergent soluble and insoluble fractions, which 
were analyzed by western blotting for SYK, G3BP1, TIA-1 and pEIF2α. SA and Aβ 
showed an increase in protein levels in insoluble fractions under treatment. 
Figure 3.6 SG markers like SYK, G3BP1, TIA-1 and pEIF2α expression 






3.5 SYK associates with other SG core components in BV-2 cells 
 
SG core components associate with other translation initiating factors, mRNA-binding 
proteins and proteins that interact with core components. To further confirm an 
interaction or association of SYK with SG markers, I expressed SYK-EGFP in BV-2 
cells, which were then treated with SA or Aβ for 24 hours. Following treatment, cells 
were lysed and SYK-EGFP was immunoprecipitated using GFP-TRAP beads. 
Immunoprecipitated SYK-EGFP was immunoblotted for endogenous SYK, G3BP1 and 
pEIF2α. Both stress stimuli resulted in an increased association of SYK-EGFP with 









































Figure 3.7 SG markers G3BP1and pEIF2α associate with GFP-tagged SYK in 
SYK-EGFP-expressing BV-2 cells 
Figure 3.7 SYK-EGFP was immunoprecipitated from 
lentiviral-infected BV-2 cells using GFP-trap beads. Cell 
lysates (Input) and immune complexes were analyzed by 
western blotting using antibodies against GFP, SYK, G3BP1 







3.6 SYK is active when present in SGs 
 
SYK is a protein tyrosine kinase that phosphorylates its substrates to regulate signaling 
pathways. In immune cells like macrophages and microglia, active SYK mediates 
downstream signaling that could activate pathways producing reactive oxygen and 
nitrogen species. To determine if SYK was active when recruited to SGs, I stained 
control and SA- and Aβ-treated N9 and BV-2 cells with antibodies against SYK and 
phosphotyrosine. SYK-positive puncta induced by either stimulus contained abundant 
phosphotyrosine indicating that SYK was active in SGs (Fig. 3.8A and 3.9). 
Quantification of images confirmed a significant increase in area containing co-localized 
SYK and phosphotyrosine in treated compared to control N9 cells (Fig. 3.8B). Western 
blotting of lysates of control and SA- or Aβ-treated N9 cells with antibodies specific for 
the phosphorylated activation loop of SYK confirmed that SYK was active and 
phosphorylated in response to both stimuli (Fig. 3.8C).   To further confirm the presence 
of active SYK in SGs biochemically, I immunoprecipitated tyrosine-phosphorylated 
proteins from control, SA- and Aβ-treated N9 cells using magnetic beads and 
immunoblotted the immune complexes for phosphotyrosine and SYK. Induction of SGs 
with either stimulus resulted in a significant increase in the phosphorylation of multiple 






























Figure 3.8. (A) N9 cells were treated without (Control) or with SA or soluble Aβ 
for 24 h, fixed and stained for SYK (green) and phosphotyrosine (pTYR, red). 
Examples of SGs are indicated by the arrows. Bar = 10 µm. (B) The area 
occupied by SYK and phosphotyrosine positive SGs in (A) was quantified by 
ImageJ analysis of 5 random frames from 3 independent experiments. Results 
represent means ± SEM. *P = 0.001.  (C) Lysates from N9 cells treated without 
(Control) or with SA or soluble Aβ for 24 h were analyzed by western blotting 
using antibodies against SYK phosphorylated on Y519 and Y520 (p-SYK), SYK 
or GAPDH.  
(D) Phosphotyrosine-containing proteins were immunoprecipitated from lysates 
of N9 cells treated without (Control) or with SA or soluble Aβ for 24 h. Immune 
complexes were examined by western blotting with antibodies against SYK or 
phosphotyrosine (pTYR).  
Figure 3.8 SYK is active when co-localized in SGs in N9 cells under treatment 


































Figure 3.9. SYK is active when co-localized in SGs in BV-2 cells under  
SA and Aβ treatment 
 
Figure 3.9 BV-2 cells were treated without (Control) or with SA or soluble Aβ for 
24 h, fixed and stained for SYK (green) and phosphotyrosine (pTyr, red). 





3.7 SYK regulates SG formation in MG under SA and Aβ treatment  
 
SG dynamics are a function of their formation and clearance. To determine if SYK plays 
an important role in SG formation, I stimulated BV-2 cells with SA or Aβ for 24 h in the 
absence or presence of a SYK inhibitor, either R406 or PRT318. In the presence of either 
inhibitor, neither SA nor Aβ induced the formation of significant SGs (Fig. 3.10A and 
3.10B). The ability of each inhibitor to reduce SYK activity was confirmed by the 
western blotting with anti-SYK and antiphosphotyrosine antibodies of lysates of BV-2 
cells treated with H2O2 in the presence or absence of R406 or PRT318. H2O2, an inhibitor 
of tyrosine phosphatases, led to the activation of SYK and its autophosphorylation on 
Y317 with a resulting shift in its electrophoretic mobility
37
, which was lost in inhibitor-


































Figure 3.10 SG formation dynamics is affected by SYK 
Figure 3.10. (A) N9 cells were treated without (Control) or with SA or soluble Aβ 
for 24 h in the presence or absence of R406 or PRT318 (PRT), fixed and stained 
for SYK (green) and G3BP1 (red). Examples of SGs are indicated by the arrows. 
Bar = 10 µm. (B) The average number of SGs formed in five random 25X frames 
were counted for each treatment. Results represent means ± SEM from 3 
independent experiments. *P = 0.0001. (C) N9 cells were treated without (-) or 
with (+) H2O2 (5 μM) for 4 h in the absence (-) or presence (+) of PRT318 or 
R406 (500 nM each). Lysates were examined by western blotting for SYK, 








3.8 Knockdown of SYK prevents SG formation in MG under SA and Aβ treatment 
 
SYK inhibitors reduced SG formation in N9 cells induced by SA and Aβ treatment. To 
confirm a direct role for SYK in SG formation, I infected BV-2 cells with lentiviruses 
expressing EGFP and either shRNA against SYK or a scrambled shRNA. SYK levels 
were selectively reduced in cells expressing the SYK shRNA (Fig. 3.11A) as confirmed 
by western blotting. Infected cells were treated with SA or Aβ for 24 hours, fixed and 
stained for G3BP1. While cells infected with scrambled shRNA readily formed SGs, cells 
with reduced levels of SYK failed to do so (Fig. 3.11B). Correspondingly, the appearance 








































Figure 3.11 (A) BV-2 cells expressing EGFP and scrambled shRNA or SYK 
shRNA were examined by western blotting with antibodies against G3BP1, 
GFP and GAPDH. (B) BV-2 cells infected with a lentivirus expressing EGFP 
and either a SYK or scrambled shRNA were treated without (Control) or with 
SA or soluble Aβ for 24 h, fixed and stained for G3BP1 (red). Examples of SGs 
are indicated by the arrows. Bar = 10 μm.  
 





























3.9 SYK promotes SG formation in primary MG 
 




Figure 3.12 (A) BV-2 cells infected with a lentivirus expressing EGFP and either a SYK 
or scrambled shRNA were treated without (Control) or with SA or soluble Aβ for 24 h, 
fixed and stained for endogenous SYK (red). Examples of SGs are indicated by the 
arrows. Bar = 10 μm. (B) Quantification of G3BP1 positive SGs present within 10 
random 25X frames for cells expressing SYK shRNA (SYK (-)) or scrambled shRNA 






MG cells lose their efficiency to phagocytose with age. Neurodegeneration is more 
prevalent in aged individuals. We used a haploinsufficient SYK mouse to conduct these 
studies. Since SYK knockout is lethal to pups, we had to use haplo-insufficient SYK 
mice to observe the role if microglial cells in old animal models. In order to first confirm 
that SYK was indeed knocked down in dead pups or reduced in haploinsufficient mice, 
we isolated liver cells from the mouse, lysed and immunoblotted for SYK and GAPDH 
(Fig. 3.13 B).  To better understand the role of age on MG, I isolated primary MG from 
20 month and 1 month old wild-type mice and haplosufficient mice. Isolated cells were 
positive for the MG marker IBA-1, but lacked the astrocyte marker GFAP (Fig. 3.13A 
and C). Cells were treated with SA or Aβ for 24 h, fixed and stained for IBA-1, SYK and 
G3BP1. Primary MG formed SYK- and G3BP1-positive puncta in response to both stress 
stimuli, which were particularly abundant in cells isolated from aged (20 month) animals 
(Fig. 3.14C). SG formation also was observed, albeit to a lesser extent, in cells isolated 
from 1 month old animals (Fig. 3.14A).  
I also asked if the dependence of SG formation on SYK held true for primary 
cells. MG isolated from the brains of SYK haploinsufficient mice expressed half as much 
SYK as cells from wild-type mice (Fig. 3.13A). Since a complete SYK knockout was 
lethal as seen previously (296), I was unable to test cells from Syk
-/-
 animals. SG 




 animals (Fig. 
3.14A, 3.15A and 3.16).  However SG formation was reduced considerably in cells 
isolated from the brains of 20 month old Syk
+/-
 mice as compared to their wild-type 



























Figure 3.13 Primary microglial culture express IBA-1and haplosufficient mice 
express reduced SYK in them  
Figure 3.13 (A) Adult primary MG were isolated from 1 month old wild-type (Wt) or 
Syk
+/-
 (Het) mice and examined by western blotting with antibodies against IBA1, 
SYK, GFAP and GAPDH. (A) Lysates of cells from fetal livers isolated from wild-
type (Wt) or Syk
-/-
 (KO) mice or from livers of 21 day old wild-type (Wt) or Syk
+/- 
mice were analyzed by western blotting for SYK and GAPDH. (B) MG were 
isolated from 1 month old wild-type (Wt) or Syk
+/-
 (Het) mice and examined by 
immunofluorescence with antibodies against IBA1, Hoechst and GFAP. Bar = 10 





















Figure 3.14 Adult primary MG from 20 month old mice generates 





upon stress induction compared to cells from 1 month old mice  
Figure 3.14. (A and B) MG isolated from the brains of 1 month old wild -
type mice (A) or 20 month old wild-type mice (B) were treated without 
(Control) or with SA or soluble Aβ for 24 h, fixed and stained for SYK, 






















Figure 3.15 Adult primary MG from 20 month old mice Syk+/- 
generate large SGs upon stress induction compared to cells from 1 
month old Syk+/- mice 
 
Figure 3.15. (A and B) MG isolated from the brains of 1 month old Syk+/- 
mice (A) or 20 month old Syk+/- mice (B) were treated without (Control) or 
with SA or soluble Aβ for 24 h, fixed and stained for SYK, IBA1 or G3BP1. 





























Figure 3.16 The average number of SGs formed in five random 63X 
frames for SYK wild-type (1 month and 20 month) and Syk+/- (1 month 
and 20 month) (Fig. 3.13 & 3.14) for each treatment. Results represent 
means ± SEM from 3 independent experiments. 
 
Figure 3.16 Quantitative comparison of SG formation in MG from young (1m) 





3.10 Prolonged chronic stress induces large and irreversible SGs in N9 cells 
 
It has been proposed that exposure to chronic stress leads to the formation of persistent 
SGs in the brain (29). AD animal model P3106 brains have also shown increased SGs 
with severity of the disease. To examine this in MG, I exposed N9 cells to low levels of 
SA or Aβ for a period of five days to mimic chronic stress. Prolonged stress led to the 
formation of large SGs that contained both SYK and G3BP1 (Fig. 3.17A). To determine 
if the formation of these SGs was reversible, I removed the stress and allowed cells to 
recover for 48 h. While the intensity of staining for G3BP1 declined somewhat, the area 
within the cell occupied by SGs was largely unchanged (Fig. 3.17A and 3.17C). In 
contrast, most SGs formed in cells exposed to SA or Aβ for only 24 h were cleared 



































Figure 3.17 (A) N9 cells were 
treated without (Control) or with 
SA or soluble Aβ for 5 days. 
Where indicated, cells were 
cultured in the absence of SA 
or Aβ for an additional 48 h. 
Cells were fixed and stained for 
SYK (green) and G3BP1 (red). 
Examples of SGs are indicated 
by the arrows. Bar = 10 µm.  
(B) N9 cells were treated for 24 
h as indicated and then cultured 
further in the absence of any 
treatment for another 24 h. 
Cells were fixed and stained as 
in (A).  Bar = 10 μm. (C) The 
area occupied by SYK and 
G3BP1 positive SGs from (A) 
was quantified by ImageJ 
analysis of 5 random frames 
from 3 independent 
experiments. Results represent 
means ± SEM. *P = 0.0001. 












3.11 Chronic stress induction leads to SYK-dependent generation of intracellular 
and extracellular ROS 
 
Activated MG can generate both reactive oxygen and nitrogen species (ROS and RNS) 
that can be damaging to neighboring neuronal cells (438). To determine if chronic stress 
led to constitutive ROS generation, I treated N9 cells with SA or Aβ for 5 days and then 
measured ROS production over the course of 1 h by monitoring the oxidation of cell 
permeant DCFDA. Cells exposed to either SA or Aβ produced substantially more ROS 
than control cells (Fig. 3.18A). Similar results were seen when I monitored the 
conversion of dihydrorhodamine 123 to rhodamine 123 as a measure of ROS production 
(Fig. 3.18C). Consistent with these results, cells chronically exposed to either SA or 
Aβ(1-42) released substantially more ROS into the media than did untreated cells (Fig. 
3.18B). ROS production in cells treated with either stress stimulus was largely attenuated 




































Figure 3.18 Chronic stress stimulation leads to increased ROS generation in 
MG cells 
Figure 3.18 (A) N9 cells were treated without (Control) or with SA or Aβ for 5 
days in the presence or absence of R406 or PRT318 (500 nM each). Cells 
were incubated with carboxy-DCFDA (10 μM) for 1 h and examined using a 
fluorescence plate reader. Data represent means ± SEM for 3 independent 
experiments. **P = 0.0001. (B) N9 cells were treated as in (A). Media was 
collected and analyzed for ROS using a chemiluminescence assay. Data 
represent means ± SEM for 3 independent experiments. **P = 0.0001. (C) N9 
cells treated as in (A) and were incubated with D123 for 1 h. Green 
fluorescence was observed using confocal microscopy. Hoechst dye (blue) was 











3.12 Chronic stress induction leads to SYK-dependent generation of intracellular 
and extracellular RNS 
 
MG cells in AD brain acquire an activated phenotype and secrete both chemokines and 
NO. The induction of NO in MG is mainly mediated by overexpression of NOS2.  I 
examined changes in the release of RNS in chronically activated MG by measuring nitrite 
levels in the media. Nitrite release increased three-fold from N9 cells that were 
chronically stimulated by SA or Aβ (Fig. 3.19B). Again, levels were reduced 
significantly if cells were activated in the presence of a SYK inhibitor. Since the 
formation of RNS in MG is mediated by NOS2 (6), I measured NOS2 levels in control, 
SA- and Aβ-treated N9 cells (Fig. 3.19A and B). An increase in the expression of NOS2 
was observed by western blotting and immunofluorescence following both stress stimuli. 
The induction of NOS2 was reduced substantially in cells in which the activity of SYK 
































Figure 3.19. Chronic stress stimulation leads to increased RNS generation by 
MG cells 
Figure 3.19. (A) N9 cells were treated without (Control) or with SA or Aβ for 5 days 
in the presence or absence of R406 or PRT318 (500 nM each). Following 
treatment, cells were fixed, immunostained with antibodies against NOS2 and 
observed using confocal microscopy. Hoechst dye (blue) was used to stain the 
and analyzed for nitrite levels using a fluorescent plate reader. Data represent 
means ± SEM for 3 independent experiments. *P = 0.001. (C) N9 cells were 
treated as in (A) and cells were lysed in NP-40 lysis buffer. Lysate was 








3.13 Chronic stress induced MG cells mediated neuronal cell death through ROS 
and RNS secretion 
 
Since ROS and RNS increased in chronically stressed MG, I asked if this could 
contribute to neuronal cell death. To test this, I co-cultured HT22 neuronal cells with N9 
cells separated by a transwell insert. When chronically SA- and Aβ-treated N9 cells were 
cultured with healthy HT22 cells for two days, I observed a significant increase in 
annexin V binding to HT22 cells (Fig. 3.20A). Negligible annexin V staining was 
observed when HT22 cells were cultured with N9 cells that were pretreated with SA or 
Aβ in the presence of PRT318. To confirm an increase in ROS and RNS in the co-culture 
media containing activated N9 cells, I measured the levels of each generated over the two 
day incubation period. A substantial increase in both ROS and RNS was observed when 
SA- or Aβ-treated N9 cells were co-cultured with HT22 cells (Fig. 3.20B and C). The 




































Figure 3.20. (A) N9 cells were treated without (Control) or with SA or Aβ for 5 days in the 
presence or absence of R406 or PRT318 (500 nM each). Following treatment, N9 cells were co-
cultured with HT22 for another 48 h separated by a transwell insert. HT22 cells were incubated 
with FITC Annexin V (green) for 30 min, fixed and imaged using confocal microscopy. Hoechst 
-
cultured as in (A). Media was collected from the co-culture experiment and analyzed for levels of 
ROS (B) or RNS (C) in media using a chemiluminescence assay and fluorescence assay as 
describe 
ed previously (Fig. 3.17B and 3.18B). Data represent means ± SEM for 3 independent 
experiments. **P = 0.0001.   
Figure 3.20. Chronically stressed MG cells induce apoptosis of HT22 neuronal 








3.14 Chronic stress induction in BV-2 and N9 cells impairs phagocytosis of pH 
sensitive E.coli Rhodo particles 
 
An important function of MG that is compromised in aged and AD brains is phagocytosis. 
To determine if chronic stress negatively affects phagocytotic activity, I treated BV-2 or 
N9 cells with SA or Aβ for 5 days and then assayed the cells for the uptake of pH 
sensitive E. coli BioParticles, which fluoresce only following ingestion. Cells were either 
fixed and stained as shown for BV-2 cells (Fig. 3.21A) or examined by live cell imaging 
for N9 cells. For both cell types, chronic stress induced by either SA or Aβ strongly 
impaired the uptake of the pHRhodo particles. Phagocytic activity was inhibited as well 
when cells were treated with either R406 or PRT318 even in the absence of SA or Aβ 
supporting an important role for SYK in phagocytosis (Fig. 3.21A and B). Uptake of 
pHRhodo particles was blocked by the incubation of cells with cytochalasin D, an 

































Figure 3.21 Chronic SA and Aβ stimulation and SYK inhibition impairs 
phagocytosis of E.coli Rhodo particles in BV-2 cells 
Figure 3.21. (A) BV-2 cells were treated without (Control) or with SA or soluble Aβ for 5 days in 
the presence or absence of R406 or PRT381 (500 nM each) and examined for the uptake of 
pHRodo particles (red). Cells were fixed and examined by confocal microscopy. Hoechst dye 
(blue) was used to stain the nucleus. Bar = 10 µm. Similar observations were made using N9 cells 
examined by time lapse live cell imaging. (B) Quantification of (A) showing change in mean 
fluorescence measured by Image J from ten random frames in three independent experiments. *P 
= 0.001, **P = 0.0001. (C) N9 cells incubated for 4 h without or with cytochalasin D (10 μM) were 
examined for the uptake of pHRodo particles (red). Cells were fixed and examined by confocal 










3.15 Chronic stress in SG in MG prevents phagocytosis of  β-amyloid fibrils 
 
An important function of MG is to clear β-amyloid plaques. To examine the effects of 
stress on this process, I treated N9 cells with SA or Aβ for 5 days and measured the 
uptake of fluorescein-labeled Aβ fibrils. Again, control cells readily phagocytosed Aβ 
fibrils whereas chronically stressed cells were unable to do so (Fig. 3.22A and B). Similar 
to soluble Aβ, Aβ fibrils also induced the formation of SGs containing both SYK and 

































Figure 3.22. (A) N9 cells treated without (Control) or with SA or soluble Aβ for 5 days were 
incubated with FITC-labeled Aβ fibrils for 12 h, washed, fixed and examined by confocal 
microscopy. Hoechst dye (blue) was used to stain the nucleus. Scale= 10 μm. (B) 
Quantification of images from (A) by Image J analysis of 5 random frames from 3 
independent experiments. Results represent means ± SEM. **P = 0.0001. (C) BV-2 or N9 
cells were incubated without (Control) or with Aβ fibrils for 24 h. Cells were fixed and stained 
with antibodies against Syk (green) and G3BP1 (red).  Only merged images are displayed. 
Arrows indicate the locations of SGs. Bar = 10 μm.   
Figure 3.22 Chronic SA and Aβ stimulation impairs phagocytosis of FITC-Aβ 









3.16 SYK associated SGs are formed in brains of AD patients 
 
Our studies on MG indicated a connection between prolonged stress and the development 
of persistent SGs to which SYK was recruited. To determine if a similar mechanism was 
operative in AD, I examined brain samples from patients with no, mild, moderate or 
severe AD (Table 1). Paraffin-fixed sections of brain cortex were stained with antibodies 
against IBA1, SYK, G3BP1 and/or phosphotyrosine. SYK was diffusely distributed in 
MG in patients with no AD and in patients with mild disease, but was increasingly 
present in large puncta with escalating disease severity (Fig. 3.23). SYK co-localized 
within these puncta in diseased brain with both G3BP1 and phosphotyrosine indicating 
















Table 1. Characteristics of Alzheimer’s disease patients used to measure SYK, G3BP1 



































Normal 6 77 30 3 2 148 234 
Mild 6 91 26 1.5 4 268 435 
Moderat
e 
6 91 22 7 5 675 746 




The mean area occupied by SGs positive for SYK and G3BP1 or SYK and pTYR was 
quantified by Image J analysis of 5 random frames from 6 different patient slides of each 



































Figure 3.23 (A and B) Paraffin embedded slides of human brain cortex from patients 
with no (Normal), mild, moderate (Mod) and severe AD were immunostained for IBA1 




























Figure 3.24 SYK and G3BP1 positive granules co-localized in human AD brain 
samples  
Figure 3.24 Paraffin embedded slides of human brain cortex from patients with no 
(Normal), mild, moderate (Mod) and severe AD were immunostained for SYK and 



























Figure 3.25 SYK positive granules co-localized with phosphotyrosine in human 
AD brain samples  
 
Figure 3.25 Paraffin embedded slides of human brain cortex from patients with no 
(Normal), mild, moderate (Mod) and severe AD were immunostained for SYK and 






3.17 IgG treatment can repair impaired phagocytosis of MG after chronic stress 
induction. 
 
Since phagocytosis of MG was impaired under SA or Aβ stimulation, I wanted to devise 
a way for cells to recover from phagocytosis impairment. I asked if manipulations of 
SYK activity or localization might restore the ability of chronically stressed MG to 
phagocytose foreign particles. Since integrin ligation leads to the activation of SYK in 
macrophages (439), I first treated chronically stressed N9 cells with rabbit IgG directed 
against β1 integrin. Treatment of stressed N9 cells for 4 h led to a marked recovery of 
phagocytic activity (Fig. 3.25). As a control, I treated stressed N9 cells with nonspecific 
rabbit IgG isotype control antibodies. Interestingly, phagocytic activity again was 
restored. To explore this further, I treated stressed cells with an affinity purified rabbit 
IgG directed against a peptide from the cytoplasmic C-terminus of the inhibitory receptor 
CD32, an antibody that should neither react with intact MG nor activate SYK. Again, 
incubation with this antibody led to a recovery of phagocytic activity in chronically 
stressed cells (Fig. 3.25). Thus, phagocytic activity in stressed MG could be restored by 
treatment with IgG independent of the specificity of the antibody.  
 
To explore the mechanism further, I examined the effects of IgG on the localization of 
SYK. Treatment of N9 cells with either non-specific rabbit IgG or the anti-CD32 
antibody led to a relocalization of SYK from the cytoplasm to the plasma membrane, the 
site where phagocytosis takes place. Even in chronically stressed cells, a substantial 





of detergent-soluble and -insoluble fractions of N9 cells confirmed the partial re-location 
of SYK from the insoluble fraction in which SGs are located to the detergent-soluble 
















































Figure 3.26. N9 cells were treated without (Control) or with SA or soluble Aβ 
for 120 h. At 116 h, to one set of control, SA- and Aβ-treated cells were 
treated with anti-1-integrin (-Int), mixed rabbit IgG (IgG) or anti-CD32 for 
the final 4 h. Cells were then incubated with pHRhodo particles (red) to 
measure phagocytosis. Cells were fixed and stained with Hoechst dye (blue) 
to visualize the nucleus. Bar = 10 m. 
 




























Figure 3.27. IgG treatment of chronically stressed N9 cells relocalizes SYK to 
the plasma membrane 
 
Figure 3.27. N9 cells were treated without (Control) or with SA or soluble Aβ 
for 120 h in the presence or absence of R406 or PRT318 (500 nM each). At 
116 h, to one set of control, SA- and Aβ-treated cells were treated with 
mixed rabbit IgG (IgG) or anti-CD32 for the final 4 h. Cells were then fixed 




















Figure 3.27 (A and B) N9 cells were treated without (Control) or with SA or soluble Aβ 
for 120 h. At 116 h, one set of control, SA- and Aβ-treated cells were treated with anti-
CD32 (A) or rabbit IgG (Rab IgG) (.B) for the final 4 h. Cells were separated into 
detergent soluble and insoluble fractions, which were analyzed by western blotting for 
SYK and GAPDH. 
A 
B 
Figure 3.28 IgG treatment of chronically stressed N9 cells partially relocalizes 










CHAPTER FOUR: DISCUSSION 
 
Paradoxically, MG from aged and AD brain exhibit a phenotype that combines a 
perpetually activated state with functionally impaired phagocytic activity (3, 6). To 
explain this dichotomy, we propose a model in which the altered activity and localization 
of SYK contributes to both phenotypes. In this model, chronic stress leads to the 
formation of SGs to which SYK is recruited resulting both in a persistent pro-
inflammatory phenotype and impaired phagocytosis.  
SG formation is thought to be, at least initially, a defense against stress, providing 
a mechanism for the selective sequestration and protection from degradation of a subset 
of mRNAs (27). However, it is clear that persistent formation of RNP particles is 
deleterious to cells as noted for several neurodegenerative disorders where aggregates 
appear in neuronal cells (31, 40). Our data indicate that SGs form, as well, in MG. In fact, 
MG appears particularly susceptible to the stress-induced formation of SGs as their 
induction requires exposure only to low levels of SA. The recruitment of SYK to SGs in 
non-inflammatory cells protects them from stress-induced damage by stimulating SG 
clearance through autophagy, an event that requires both SYK activity and its association 
with SGs (Krisenko et al., manuscript submitted for publication). This process may be 
operative as well in MG as SGs can be cleared effectively from MG exposed to stress for 





associate with SYK and are resistant to clearance as they persist following removal of the 
stimulus. SYK in SGs is active as reflected by the presence of phosphotyrosine-
containing proteins, which is a function of SYK’s catalytic activity (Krisenko et al., 
manuscript submitted for publication). Large SGs also are characteristic of MG in the 
brains of patients with advanced AD, and these also contain abundant SYK and 
phosphotyrosine. Thus, the appearance of SYK- and phosphotyrosine-containing puncta 

























SA induces SG formation in part through the generation of ROS
41
. Oxidative stress also 
is thought to precede the pathogenesis of AD since enhanced neuroinflammation 
resulting from traumatic brain injury, infection, or aging predispose individuals to AD 
while the long-term use of NSAIDS can be protective
 
(440). We find that when stress 
stimulates the formation of SGs in MG this hampers their ability to phagocytose Aβ(1-
42) fibrils. Thus, we predict that enhanced accumulation of Aβ plaques in the brain would 
be an expected result of a prolonged exposure to oxidative stress. We find further that the 
exposure of MG to Aβ or Aβ fibrils alone also induces the appearance of abundant SGs. 
This is consistent with the known ability of Aβ to trigger MG cell activation and promote 
the generation of ROS and RNS (9, 376). Thus, a defect in the removal of Aβ fibrils by 
MG compromised by oxidative stress could cause a build-up of Aβ plaques leading to 
additional Aβ-induced stress and the enhanced formation of persistent SGs. MG from 
aged mice are more sensitive to the stress-induced formation of SGs suggesting one 











The formation of SGs in MG in response to low levels of either SA or Aβ requires the 
expression of SYK as it is blocked by SYK inhibitors or by a knockdown or reduction of 
SYK expression. In inflammatory cells like MG, SYK plays a well known role in the 
receptor-mediated production of ROS and RNS (271). Aβ binds to MG via an assortment 
of cell surface receptors (6) many of which, including CD14, TLR4, CD36, and SIRPβ1, 
are coupled to SYK either directly or through receptor-associated proteins that contain 
ITAMs (254, 367, 383, 441, 442). SYK also is activated in cells under conditions of 
increased oxidative stress (443). The resulting SYK-dependent pro-inflammatory 
response may be further exacerbated by the retention within SGs of active SYK, which 
may continue to stimulate down-stream signaling pathways that generate ROS or RNS. 
The production of ROS and RNS can be damaging to neighboring cells
 
(6) and we find, 
in fact, that chronically activated MG produce mediators that are toxic to HT22 neuronal 
cells. Consistent with a role for SYK in these processes, the generation of chronically 
activated MG that produce ROS and RNS and the ability of these cells to kill neuronal 
cells are all blocked by SYK inhibitors.  
The ability of MG to clear Aβ plaques through phagocytosis is important for the 
control of AD (5, 439). We find that chronic stress induced by prolonged exposure of 
MG to either SA or Aβ inhibits the ability of these cells to phagocytose either bacteria or 
Aβ fibrils. Interestingly, in a mouse model of AD, the phagocytic activity of MG also is 
selectively compromised in brain regions containing Aβ plaques (4). We find that chronic 
stimulation of MG with either SA or Aβ results in the formation of very large SGs to 





phagocytic receptors that underlies the impaired phagocytic activity of MG encountering 
Aβ plaques.  
A role for SYK in both phagocytosis and the activation of MG complicates the 
development of strategies for the use of specific SYK inhibitors for the treatment or 
prevention of AD. However, the finding that active SYK is sequestered in SGs suggests 
that strategies to relocate the enzyme might be effective in restoring some function to 
damaged MG. We find that the treatment of chronically stressed MG with rabbit IgG 
leads to a dramatic restoration of phagocytic activity. The recovery of activity is not a 
function of the reactivity of the IgG to any specific antigen as even an affinity-purified 
antibody prepared against a peptide found on the cytoplasmic domain of an ITIM-
containing receptor is able to induce this effect. Treatment of MG with IgG leads to a 
relocalization of SYK from the cytoplasm to the plasma membrane in unstressed cells 
and from SGs to the membrane in chronically stressed cells. This effect may help explain 
the therapeutic benefits of intravenous immunoglobulins (IVIg), which have shown 
efficacy in slowing the progression of AD in some human clinical trials (444-446). The 
benefits of IVIg are generally attributed to the presence of anti-Aβ antibodies in the 
pooled IgG preparations (444). However, it is interesting to note that the administration 
of pooled mouse IgG having no detectable anti-Aβ activity to the brains of APP/PS1 
mice leads to a similar reduction in Aβ deposits as does IVIg (447). Thus, even 
immunoglobulins that fail to recognize Aβ have the potential to reverse defects in the 
function of stressed MG. This observation suggests that the development of IgG-related 
therapeutics optimized for the recovery of phagocytic activity of MG would be an 






CHAPTER FIVE: FUTURE DIRECTIONS 
 
Stress granule formation in neurodegenrative brain has been observed in several diseases 
including ALS, AD, SMA and FXMR(29). Autopsy studies on the brains of these 
patients have indicated an increased aggregation of SG-associated proteins with 
increasing severity of the disease. Our studies showed for the first time the presence of 
SGs in MG. MG over-activation is the leading cause of neuroinflammation in 
neurodegenerative diseases. Our data show that SYK promotes SG formation in MG 
under SA or Aβ mediated stress. It would be very interesting to further dissect the other 
stressors that influence the formation of SGs in MG. We know, for example, that several 
genetic mutations in genes like tau, PINK1, PARKIN, APP, SNCA, CDK5, MST1 and 
prion directly manifests disease symptoms (448, 449). To better understand the role of 
SGs in these diseases, it would be interesting to examine these mutant proteins to 
determine if they directly or indirectly drive SG formation or inhibit SG clearance in the 
brain during disease progression. 
In this study, we discovered that chronic stress at a very low dose can induce SGs that are 
persistent and cannot be removed upon removal of stress. We also observed that SYK 
localizes in SGs and influences their formation in these cells. Additionally, SYK 





 indicated that excessive production of ROS and RNS hastens neuronal cell death through 
chronic neuroinflammation. Our study also showed that SYK associates with other 
misfolded proteins like TDP-43 upon stress stimulation. Syk was also observed to be 
active in these SGs. SYK is a tyrosine kinase that phosphorylates several downstream 
proteins to trigger activation of other pathways such as Ras/ERK and activate 
transcription factors such as NF-κB (138, 224, 450). These downstream proteins directly 
or indirectly modulate release of pro-inflammatory factors, cytokines or reactive species 
in various cells including immune cells. A proteomic screen of MG under acute or 
chronic stress will help to identify the proteins that associate with SYK in SGs under 
chronic stress. Furthermore, we can also identify the major pathways that are activated 
that result in SG formation. It is well known that SYK associates with ITAM bearing 
receptor proteins in MG. A detailed tyrosine phosphoproteomic screen could identify the 
receptors that activate SYK under SG formation conditions. Several MG receptors like 
FcɣR, integrins, CD33 and CD-3 are involved in engulfing Aβ plagues and tau tangles in 
AD (341, 451). The screening could also reveal the receptors that lose their ability to 
engulf foreign particles like misfolded proteins under chronic stress.  
Autophagy is a mechanism by which cells get rid of intracellular protein 
aggregates and damaged organelles. The intracellular proteins are engulfed by double 
walled vacuoles and delivered to lysosomes for degradation. In neurodegenrative diseases, 
studies have shown that autophagy mediates removal of impaired organelles and toxic 
protein aggregates like HTT, tau and beta amyloid. Impairment of autophagy is also 
observed in neurodegenrative diseases like AD, PD and HD (32, 410). Additionally, 





HD. On the other hand, it has been reported in a few studies that autophagy could be one 
of the mechanisms by which SGs are cleared from the cell. Based on such evidence, it 
could be proposed that impairment of autophagy leads to an increase in the number of 
pathological SGs in neurodegenrative brain. Due to reduced autophagy, a greater number 
of toxic protein aggregates are sequestered to the SGs and a chain of downstream 
unfavorable reactions occur. Understanding the connection between autophagy and SGs 
in neurodegenrative brain, specifically MG, could provide us with better therapeutic 
approaches to retarding disease progression. It would be also interesting to examine if 
promoting autophagy would increase clearance of pathological SGs resulting in alleviated 
disease symptoms. 
 One of the vital functions of MG is phagocytosis of protein aggregates, debris and 
dead cells. MG efficiently perform phagocytosis of amyloid plagues and tau fibrils in 
early AD brain, but fail to do so with disease progression. Additionally MG adopt an 
activated state, releasing cytokines, chemokines and reactive species contributing to 
inflammation (124, 430). In our study, we have shown that inhibition of SYK in Aβ 
stressed MG can prevent the generation of such reactive species. Sadly, SYK inhibition 
also impairs phagocytosis. But another finding in our study also showed that IgG 
treatment can re-localize SYK partially to the plasma membrane from SGs. This re-
localization reconstituted the phagocytosis machinery in MG and the number of SGs also 
was reduced. Further studies need to be done to dissect which receptors IgG binds to on 
the membrane to provoke such a relocalization of SYK. It would be interesting to 
determine if the binding of IgG Fc regions to the receptors is enough to relocalize SYK 





and SYK relocalization could prove to be a promising therapeutic approach for repairing 
MG in AD. 
 Since this study led to some interesting findings about SYK’s role in MG 
activation in AD; it would be logical to expand this study to neurodegenrative animal 
models. APP/PS1 is a very suitable mouse transgenic model to study Aβ mediated 
neurodegeneration in AD (131, 222). Our study suggests that SYK inhibition and IVIg 
can be a promising therapeutic approach to repair impaired MG in AD. An animal model 
study involving use of SYK inhibitors and IVIg independently or in combination in 
APP/PS1 transgenic mice would be interesting. Examination of neuroinflammation and 
MG activation in those animal models will tell us more about microglial SYK’s role in 
AD. Additionally, behavioral studies would also help us determine the importance of this 
study in the development of therapeutics. 
  Primary MG when stressed with SA or Aβ developed large SYK and G3BP1 
positive SGs. MG from 20 month old mice showed large SGs compared to 1 month old 
mice. Further examination in SYK haplosufficient mice showed reduced SGs in stressed 
MG confirming SYK’s role in SG formation. Since the SYK knockout mouse is 
biologically lethal, we are trying to develop a transgenic mouse that expresses an analog 
sensitive form of SYK (296). Treatment with an orthogonal inhibitor like NM-PP1 can 
inhibit SYK’s activity selectively in these mice at any point in their life cycle (452). It 
would be interesting to examine the SG dynamics in MG of these mice upon Aβ stress 
induction. Subsequent investigation of MG in this genetically modified SYK mouse 
could give us insights into receptors that are impaired upon SYK knockdown in the long 





knockdown in an adult mouse. The next step would be to develop a transgenic mouse by 
genetically crossing analog sensitive form of SYK knockout mouse and APP/PS1 mice. 
Such transgenic mice can further help us to dissect the exact role of SYK in overall 
progression of AD. By turning off SYK at any specific time point in the life cycle of such 
transgenic mice, we can identify the role of microglial SYK in early and late AD. We can 
also determine the various SYK associated ITAM receptors that are activated and 
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